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Abstract
Over the past half century, obesity has become a widespread concern to human health.
Obesity is defined as having a body mass index above 30 and is accompanied by altered metabolic
physiology. Obesity is one of the leading causes of mortality in the United States and in the world.
The prevalence of obesity [1] has increased over the past few decades. High body fat in adipose,
excess calorie intake, low aerobic fitness are all associated with the comorbidities of obesity [2,
3] [4-6] [7-13]. Recently, an emphasis has been given to increased leukocytes in adipose tissue
and the resulting low-grade systemic inflammation on the development of insulin resistance [46]. Unfortunately, the immune-metabolic molecular mechanisms by which increased
inflammation leads to diseases is not fully understood.
We studied Nucb2, a highly expressed gene in immune cells and encodes for nesfatin-1,
a peptide reported to be a satiety signal [14]. We saw that Nucb2 expression is increased in
leukocytes of high fat diet (HFD) fed animals. Contrary to our hypothesis, Nucb2-/- animals
showed no effect on food intake. We then performed euglycemic hyperinsulinemic clamp studies
in wild type and Nucb2 mice on a chow diet and a HFD to determine insulin sensitivity.
Interestingly, knocking out the Nucb2 gene significantly impaired insulin sensitivity only under
HFD conditions. These experiments demonstrate that Nucb2 is key player in glucose homeostasis
in obesity.
We discovered macrophages deficient of Nucb2 impact the proinflammatory
macrophages. Macrophages lacking Nucb2 increased proinflammatory cytokine production. This
suggests that Nucb2 intrinsically regulates the inflammatory cytokine production cascade.
Mechanistically, Nucb2 mediates its effects by increasing proinflammatory cytokine
expression via down-regulation of NFκB signaling in leukocytes. In the absence of Nucb2, NFκB
activity is increased in macrophages. In contrast, inhibiting NFκB caused the opposite response.
Finally, in response to endotoxemia, Nucb2 is required to control the production
proinflammatory cytokines. Collectively, these data highlight a novel mechanism whereby Nucb2
serves as a key mediator of immunometabolic control of inflammation and insulin resistance.
Overall, the studies I have performed identified a novel mediator of the immune-metabolic cross
talks in the context of obesity-induced insulin resistance.

ix

Chapter 1: Introduction
1.1 Background and Significance
Obesity is a disease that has recently reached epidemic proportions in developed as well
as in developing countries [15], and is now recognized as a more complex condition than once
believed. Obesity is a multifactorial condition in which environmental risk factors related to a
sedentary life-style and excess access to food apply constant pressure in subjects with a genetic
predisposition to gain weight [16]. The role of genetics in obesity is complex, as it involves the
interaction of many genes which may each have relatively small effects, yet work in combination
with others and with external environmental factors to ultimately cause weight gain. Despite
evidence that genes are involved in the variation of body fat in humans, no major obesity gene
was identified until the ob gene was discovered in mice [17]. However, the absence of leptin (the
product of the ob gene) is affecting only a few people in the world. As obesity has become more
prevalent throughout the world, researchers have found a strong association between obesity
and type 2 diabetes, now also reaching epidemic levels around the world.
Type 2 diabetes is characterized by a decrease in glucose uptake in cells (such as muscle,
liver and adipose) resulting, in part, from defects in insulin sensitivity. This decrease in insulin
sensitivity is often further affected by defects in insulin secretion. Together, these deleterious
consequences of insulin resistance and progressive beta-cell failure to secrete insulin results in
increased blood glucose levels, leading to blood vessel damage and eventually to tissue and organ
failure [18, 19].
Recently, evidence has been found for a connection between inflammation in adipose
tissue and insulin resistance. Adipose tissue is traditionally considered to be a long-term energy
storage organ, but now, it is also known to play key roles in the integration of systemic
metabolism. Excess body fat leads to systemic inflammation [20]. This inflammatory state is
initiated largely in the adipose tissue, which itself releases cytokines, adipokines and fatty acids.
Downstream, deleterious effects could ensue on the liver and in the muscle which are key organs
and tissues for the regulation of whole body glucose metabolism [6, 20-22].
The immune system includes many complex biological structures and processes within an
organism that protects against disease. A properly functioning immune system must detect a
wide variety of agents, known as pathogens, from viruses to parasites, and distinguish them as
foreign from the organism’s own healthy tissues. Another fundamental feature of a properly
functioning immune system is the ability to terminate the immune response after the resolution
of infection. This is necessary to prevent autoimmunity and to reduce ongoing inflammation.
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Unfortunately, the molecular mechanisms or regulatory genes that mediate the immunemetabolic crosstalk that drive obesity-related inflammation and chronic diseases are not fully
understood. For example, several satiety regulatory peptides that act on the hypothalamus and
act as long-term signals of energy balance, can also activate many immune cells. Ghrelin and
leptin, for example, are produced in peripheral sites such as the gut and adipose tissue
respectively and play roles in body weight regulation as well as immune cell functions.
Dysregulation of these immune functions can therefore contribute to the pathophysiology of
insulin resistance and its associated metabolic complications such as diabetes [4-6].
As a consequence, special efforts have recently focused on understanding the molecular
mechanisms of “sterile inflammation”. The specific mechanisms and regulatory genes that drive
metabolic-related inflammation and chronic diseases via mediation of the immune-metabolic
crosstalk are not fully comprehended. Emerging genes, such as nucleobindin-2 (Nucb2) and
Nesfatin-1 are required for maintenance of normal immune-metabolic interactions. As an
example, Nesfatin-1, a proteolytically cleaved peptide of Nucb2, has been shown to be a potent
anorexigenic protein reducing food intake in rodents when administered either centrally or
peripherally [14, 23]. Furthermore, through expression profiling studies of immune and
metabolic tissues, we found a high level of Nucb2 in both immune/metabolic tissues and cells,
and Nucb2 expression is responsive to changes in dietary energy intake in adipose derived
leukocytes. Based on recent literature and these expression profiling studies of Nucb2, we
hypothesized that Nucb2 plays a critical role in crosstalk of immune-metabolic axes. More
specifically, such immune-metabolic axis may be involved in the regulation of food intake and
consequently insulin resistance and glucose homeostasis. To investigate the role of Nucb2 in
embryonic development as well as in physiological homeostasis, we used a gene targeting
homologous recombination technique to design a mouse Nucb2 loxP-floxed allele for the
generation of a Nucb2 knockout model.
My dissertation focuses on the roles of innate and adaptive immune system in the
pathogenesis of obesity related metabolic disease.

1.2 Metabolism, Obesity and Type 2 Diabetes mellitus
Energy metabolism
Energy metabolism is the general process by which living cells acquire and use the energy
needed to stay alive, grow and reproduce. Mammals generate energy from nutrients, including
fats, carbohydrates and proteins. Of the three, fat is the most concentrated source of energy, as
it provides two times more energy per unit weight than protein or carbohydrates. Metabolic
processes are complex, and involve the coupling between the oxidation of nutrients and the
2

synthesis of high-energy compounds, particularly adenosine 5-triphosphate (ATP), which works
as the main energy molecule in all cells.
There are two mechanisms of ATP synthesis; the first involves oxidative phosphorylation
through a process by which ATP is synthesized from ADP and inorganic phosphate. The second,
substrate-level phosphorylation, is the process by which ATP is synthesized through the transfer
of high-energy phosphoryl groups from high-energy compounds to ADP. Both processes occur in
the mitochondrion. Indeed, oxidative phosphorylation utilizes the mitochondria’s structure,
enzymes and energy released by the oxidation of nutrients to form ATP. Substrate level oxidation,
however, occurs in the mitochondria via the tricarboxylic acid cycle (TCA) and in the cytoplasm
during glycolysis.
Carbohydrate, protein and fat oxidation are the main source of energy in the cell and all
converge on the TCA cycle. The beginning of the metabolic pathway for glucose catabolism is
glycolysis, which occurs in the cytoplasm. Glycolysis converts glucose to pyruvate and synthesizes
ATP. Pyruvate is then transported from the cytoplasm into the mitochondrial matrix. Fatty acids
are transported from the cytoplasm to the mitochondrial matrix, with the help of Coenzyme A,
to form a temporary compound called acyl-CoA. Acyl-CoA is then converted to acetyl-CoA
through β-oxidation reactions, which release electrons that are carried by NADH and FADH2.
Amino acids are transported from the cytoplasm to the mitochondrial matrix, and then, broken
down in transamination and deamination reactions. The products of these reactions include
pyruvate, acetyl-CoA, oxaloacetate, fumarate, alpha-ketoglutarate, and succinyl-CoA, which
enter at specific points during the TCA cycle [24].
Different cell types utilize and regulate these catabolic and anabolic energy processes in
different manners. Some cell types are more glycolytic, using more glucose, while other cell types
utilize more fatty acids in oxidative metabolism. Conceptually, it is easily imagined that certain
cells require constant energy sources, whereas others might require fewer or infrequent energy
sources, and thus the metabolism of a cell can change over time. For example, there is a clear
metabolic difference that exists between classically activated M1 and alternatively activated M2
macrophages. An M1 macrophage is crucial for defense in the initiation of innate immune
responses, whereas M2 macrophages play a bigger role within the resolution phase and require
much longer-term functions. The difference in metabolic processes between these two related
cell types reflects their functions. M1 macrophages undergo aerobic glycolysis upon activation,
whereas M2 cells obtain much of their energy from β-oxidation and oxidative metabolism, which
can be sustained for longer periods of time [25].

3

Figure 1.1: Overview of typical energy metabolism processes in a macrophage
A schematic diagram of a macrophage showing how fuel molecules have many different entry points in oxidative
metabolism. The smaller dark blue oval contained inside the cell represents the mitochondrion. The mitochondrion
has an outer mitochondrial membrane and a folded inner mitochondrial membrane that surrounds the
mitochondrial matrix. The ETC (electron transport chain) is represented by a yellow rectangle along the inner
mitochondrial membrane. The electrons are transported to the ETC where ATP is synthesized using the protein ATP
synthase [24].

For more details on substrate (glucose and lipid) metabolism and cellular respiration,
please refer to the appendix.
Obesity
Excess energy intake leads to increased body weight mostly in the form of excess adipose
tissue but also with some lipids accumulation in other tissues such as liver, skeletal muscle and
heart, all called ectopic fat. The World Health Organization (WHO) defines overweight and
obesity as “abnormal or excessive fat accumulation that may impair health”. Obesity is a major
risk factor for metabolic disease, diabetes, cardiovascular disease, stroke, arthritis as well as
some cancers. The excess fat mass that characterizes overweight and obesity is linked to an
4

impairment of insulin sensitivity through complex multifactorial mechanisms which are still not
fully understood. Adipose tissue dysfunctions have been recognized as essential in this link
between weight gain and impairments in insulin signaling [20, 26]. Alterations of fatty acid
metabolism leading to increased fatty acid flux cause metabolic disturbances (insulin resistance)
in the liver and skeletal muscle [27].
The underlying mechanism behind the cause of obesity, however, is a topic of debate.
Obviously, obesity results when energy intake chronically exceeds energy expenditure [28].
However, the contribution of the specific causes to the epidemic of obesity (energy intake vs.
energy expenditure) is still very much debated. The role of genetics in body fat regulation is now
well established. It is, however, safe to assume that the increased prevalence of obesity has not
been due to a genetic change in the Western world in recent history. The recent, large scale rise
of obesity must therefore be due mostly to environmental changes, including the availability and
composition of the food ingested and changes in physical activity.
Insulin signaling and type II diabetes
Without intervention designed at weight loss, obesity most likely leads to the metabolic
syndrome (a constellation of obesity, dyslipidemia, hypertension and insulin resistance) and, in
turn, to diabetes mellitus. Diabetes mellitus is defined as a metabolic disorder of multiple
etiology, characterized by chronic hyperglycemia, with disturbances of carbohydrate, fat and
protein metabolism resulting from defects in insulin secretion, insulin action, or both[29]. This
disease has become an increasing problem worldwide, and numbers from the WHO show that in
2014, 9% of adults 18 years and older had diabetes. In 2012 diabetes was the direct cause of 1.5
million deaths [30]. The WHO furthermore projects that diabetes will be the 7th leading cause of
death in 2030 [31]. The two most common forms of diabetes are type 1 (T1D; autoimmune
deficiency in β-cells and insulin secretion) and type 2 (T2D; insulin resistance leading to β-cell
failure). The WHO has estimated that 90% of people with diabetes have T2D [30].
Patients with type 1 diabetes require daily administration of insulin, a pancreatic
hormone which acts to reduce circulating glucose levels, due to deficient insulin production. T2D,
however, is characterized by insulin resistance, and eventual insufficient insulin production.
Insulin signaling is required to regulate metabolism. Elevated levels of fasting blood glucose, with
subsequent elevations in insulin levels, are often seen in patients with untreated T2D. The body
attempts to produce more insulin to overcome the elevated levels of blood glucose as a
compensatory mechanism. Failure of insulin signaling in the liver, muscle and adipose tissue leads
to hyperglycemia. Over time, T2D results in damage to blood vessels, nerves and leads to internal
organ failure [18, 19, 32-35] . Patients with T2D frequently display cardiovascular disease, stroke
and other macrovascular diseases. There are also numerous microvascular complications such as
microangiopathy in the eyes, kidneys and nerves associated with T2D [36]. Although it was
5

recorded that diabetes caused approximately 1.5 million deaths in 2012, this number is most
likely an underestimation, since many deaths in diabetic patients are documented as heart
disease or kidney failure, both common complications of diabetes [30].
A key characteristics of T2D is insulin resistance. This state of resistance induces impaired
biological responses to insulin, including decreased glucose transport, glucose oxidation and
glycogen synthesis [37]. Insulin resistance has been shown to be partly determined by increased
intramyocellular lipid accumulation and reduced muscle fat oxidation [38-41]. Several studies
have also observed lower mitochondrial number and activity in type 2 diabetics [42]. In 2008,
Turner and Heilbronn [43] published a complete summary of the differences between insulinresistant and -sensitive individuals. Based on these findings, Samuel et al (2010) postulated that
mitochondrial dysfunction would limit the capacity to match fatty acid oxidation to fatty acid
(over) supply, leading to increased muscle lipid accumulation and insulin resistance [40].
As presented above, the gradual development of hyperglycemia and diabetes involves
numerous pathogenic processes. These include the destruction of the pancreatic β-cells leading
to consequent decreased insulin and T2D. Besides ectopic fat causing an inhibition of intracellular
insulin signaling, it is now well accepted that insulin receptors can be inhibited by
immunomodulatory cytokines such as TNF-α or IL-1β [44]. Classically, insulin resistance from
obesity begins in peripheral tissues, such as liver and muscle, thus leading to an increase in blood
glucose levels. However, this effect is kept in check by compensation from the pancreatic β-cells
that respond to hyperglycemia by increasing insulin secretion [35, 45, 46]. Diabetes is attenuated
if increased insulin secretion and action keep pace with the rise in blood glucose. Although the
molecular mechanisms that underlie the metabolic impairments of T2D are still largely unknown,
insulin signaling can dramatically influence metabolic responses, as suggested by manipulation
of components of these signal-transduction pathways in species ranging from flies to humans
[47]. It appears, however, that genetic predisposition and environmental factors both play an
important role in the onset and risk for development of the disease [48, 49].
Glucose requires glucose transporters (GLUT) for entry into cells, and GLUTs are found
throughout all tissues of the body. Moreover, adipose tissue, muscle and liver require insulin for
glucose transport into the cells. Adipose tissue insulin-sensitivity, or lack of sensitivity, largely
affects whole body glucose homeostasis [50], as adipose tissue is a major regulator of systemic
production free-fatty acids but also a consumer of glucose, especially in rodents. It is therefore
no surprise that it is considered one of the primary targets for understanding mechanisms
mediating the development of insulin resistance and T2D. There are several isoforms of GLUT
proteins, and each play a specific role in glucose metabolism [51], however, it is mainly the GLUT4
isoform that is modulated by insulin action in metabolically relevant tissues [52]. A signaling
cascade triggered by the activation of the insulin receptor causes translocation of GLUT4 to the
6

cell membrane [52]. At rest, GLUT4 is sequestered in intracellular vesicles, but fuses with the
plasma membrane upon insulin response. The insulin receptor’s extracellular α-subunit binds
insulin, which leads to an autophosphorylation of the transmembrane β-subunit. Next, the insulin
receptor substrate (IRS) is phosphorylated, and can thus interact with Scr-homology-2 (SH2)
domains, which in turn activate phosphatidylinositol-3 kinase (PI3K) [47]. Activated PI3K will
further activate downstream signaling molecules and proteins like phosphatidylinositol
(3,4,5)triphosphate (PIP3), 3 phosphoinositide dependent protein kinase-1 (PDK1) and protein
kinase B (Akt/PKB), which ultimately results in translocation of GLUT4 into the membrane [47,
52].
Increased concentrations of insulin cause an increase of GLUT4 proteins in the cell
membrane, which consequently increases the glucose transport capacity of cells. Once it has
been taken up by GLUT proteins in the cell membrane, glucose is phosphorylated to glucose-6phosphate through an enzymatic reaction by hexokinase. Glucose-6-phosphate can furthermore
be utilized in the glycolytic pathway, glycolysis, or be incorporated into glycogen, by glycogen
synthase in liver and muscle. Glucose can also be stored as fat via de novo lipogenesis in some
cases [53].
The changes in glucose metabolism seen in patients with T2D are mostly due to a
transition of skeletal muscle, liver and adipose tissue into a state of insulin resistance. Garvey et
al. proposed that there is impairment in the translocation of GLUT4 from intracellular stores to
the plasma membrane, thus causing insulin’s inability to stimulate glucose uptake. This
hypothesis has been supported by several studies showing that the cells in tissues and organs of
insulin resistant subjects have a surprisingly normal GLUT4 expression, but impaired
translocation to the cell membrane [54]. Furthermore, studies on glucose uptake in muscle have
also shown reduced activity in IRS-1 phosphorylation and P13K activity in insulin resistant patient
with T2D [55, 56]. These data suggest that insulin resistance can occur at many different levels in
this pathway and that interference with one or more of these proteins can induce insulin
resistance.

7

Figure 1.2: Overview of adipocyte insulin dependent glucose uptake via GLUT4 transporter
Insulin binds to the α-subunit of the insulin receptor. This triggers a downstream cascade, which leads to the
translocation of GLUT4 to the plasma membrane. The major molecules and proteins are IRS; insulin receptor
substrate, PIP2; phosphatidylinositol (4,5)-biphosphate, PI3K; phosphatidylinositol-3 kinase, PIP3;
phosphatidylinositol (3,4,5)-triphosphate, PDK-1; 3-phosphoinositide dependent protein kinase-1, Akt/PKB; protein
kinase B, AS160; Akt substrate regulating GLUT4 translocation.

Below, we are emphasizing the role of a novel emerging mechanism leading to insulin resistance,
i.e. local and systemic inflammation.

1.3 Immunity
Every biological organism needs to protect itself against disease to ensure life and
evolutionary survival. Immunity is the body’s ability to recognize and dispose of substances which
it interprets as foreign and harmful to its well-being. While different organisms utilize different
mechanisms to safeguard themselves against potential pathogens, immunity broadly requires
complex chemical and mechanical activities to defend and protect the body’s cells and tissues.
These complex processes include the body’s ability to protect itself against specific infectious
agents and parasites, to accept or reject foreign cells and tissues (such as blood transfusions), to
protect against mutations and against cancers (recognition of malignant cells), while all at the
same time not attacking normal functioning host cells vital to life. Extensive research has been
done into the body’s ability to differentiate self-cells, organs and substances from those which
are non-self and must be eliminated.
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Throughout history, there have been several key observations that led scientists to better
understand how we protect ourselves against infections. As early as the plague of Athens in 430
BC, Thucydides’ remarkable documentation left not only a clear clinical picture of the pestilence,
but most notably described how people who had recovered from a previous bout of the disease
conferred at least partial immunity and could nurse the sick without contracting illness a second
time [57]. Further observations showed that certain species were immune to some venom, while
others succumbed to the infections. From these and other observations, Louis Pasteur
constructed a hypothesis that infections by pathogens could be attenuated by exposure to
environmental insults, leading to vaccine development and, later, the germ theory of disease
[58]. In the 19th century, rapid developments led towards great advances in the mechanism of
humoral and cellular immunity.
The immune system protects organisms from infections through a process of layered
defenses of increasing specificity. In an overgeneralized manner, physical barriers are the first
line of defense preventing pathogens from entering an organism. Our immune systems can be
further divided into the innate immune system, which provides an immediate, non-specific
response, and the adaptive immune system, which provides a more specific response and is
activated by the innate response. These systems have evolved to better protect us from
pathogens to avoid infections. Importantly, multiple defense mechanisms have evolved to keep
pace with rapidly evolving pathogens. Throughout the day, we are exposed to millions of
potential pathogens which the body is able to defend against remarkably well.
Innate immunity
Innate immunity is the first line defense mechanisms that reacts immediately, or within
hrs, to many common microorganisms (Figure 1.3). It does not confer long lasting or protective
immunity to the host, and is often the only defense in lower animals [59]. The innate immune
responses are essential for the control of common bacterial infections. This system mainly
consists of macrophages, neutrophils and dendritic cells which provide mechanisms that protect
the host from infection by other organisms. Over the past several decades, much has been
discovered about the innate immune response to microorganisms. With the identification of
pattern recognition receptors (PRR) and pathogen-associated molecular patterns (PAMP),
Medzhitov et al. showed that host defense mechanisms are more generic in the response to
pathogens via sensors of conserved microbial motifs, rather than each microbe activating a
different immune response pathway. Since these findings, many PRRs have been described, and
we now know that they are able to recognize several different PAMPs and more recently
identified Danger Associated Molecular Patterns (DAMPs). One of the most well studied families
of PRRs are the Toll-like family of receptors (TLRs) [60].
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Figure 1.3: Time course of a normal immune response with important cell types
Time-course of a typical immune response beginning with the initial microbe recognition. First, phagocytes of the
innate immune system respond and produce chemokines, inflammatory cytokines and antiviral-interferons. These
trigger Natural Killer cell responses and complement killing. The phagocytes will then activate the adaptive immune
response by antigen presentation to T and B cells. The activated lymphocytes will then undergo clonal expansion
with the antigen specific receptor. These receptors can then specifically target microbes in cell mediated T cell killing
or humoral mediated antibody production. After resolution of the microbe and immune response, activated
lymphocytes will contract by apoptosis. Some cells will retain receptors with antigen specificity and be in a quiescent
memory state for possible re-exposure to same microbe.

Innate immunity has numerous functions depending on stimuli. It is essential that the
response of the innate immune system be specific to the tissues in the immediate environment
of the infection. Firstly, the innate system is important in recruiting immune cells to the sites of
infection through the production of chemical factors called cytokines and chemokines.
Identification and removal of foreign substances present in organs, tissues, the blood and lymph
are next carried out by specialized immune cells called leukocytes. The defense systems of innate
immunity are effective in combating many pathogens. However, these defense mechanisms are
constrained by the germline-encoded receptors to recognize microorganisms that can evolve
more quickly than host cells antigen receptors they infect [61]. The innate immune function is
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also important in antigen presentation, in which the innate immune system activates the more
long term and specialized adaptive immune system [62].
Inflammation, mediated by the innate immune system, is one of the first immune
responses to infection, tissue injury or irritation. Inflammation is stimulated by chemicals
released by injured cells and serves to establish a physical barrier against the spread of infection,
to promote healing of any damaged tissue, and, finally, to clear the pathogen. The development
of acute inflammation is originated by resident immune cells present in all tissues, mainly
macrophages and dendritic cells. These cells present PRRs, which recognize molecules that are
broadly shared by pathogens but distinguishable from host molecules, collectively referred to as
PAMPs. At the onset of an infection, burn, or other injuries, these cells undergo activation (one
of their PRRs recognizes a PAMP) and release inflammatory mediators, or cytokines, responsible
for the cardinal signs of inflammation; swelling (tumor), redness (rubor), heat (calor) and pain
(dolor), which were first described in the first century by the Roman scholar Aulus Cornelius
Celsus in 1st Century DC [63, 64].
Inflammation is initially the result of the activation of resident macrophages by infectious
components, such as lipopolysaccharide acting through toll-like receptors on the macrophages.
Most PRRs respond to PAMPs by triggering activation of NFκB, AP1, CREB, C/EBP, and IRF
transcription factors [61]. Induction of these genes encoding enzymes, chemokines, cytokines,
adhesion molecules, and regulators of the extracellular matrix supports the recruitment and
activation of more leukocytes, which are critical for eliminating foreign particles and host debris.
Chemical factors produced during inflammation (histamine, bradykinin, serotonin,
leukotrienes, and prostaglandins) sensitize pain receptors, cause vasodilation of the blood
vessels and attract phagocytes, especially neutrophils. Cytokines produced by macrophages and
other cells of the innate immune system also mediate the inflammatory response. These
cytokines include TNF, IL-1β, IL-18 [61]. These cytokines promote leukocyte extravasation by
increasing the levels of leukocyte adhesion molecules on endothelial cells [65].
The cells of the innate immune system are critical for the initiation and subsequent
direction of the adaptive immune response. They are also important in the removal of pathogens
that are targeted by an adaptive response. A critical cell type that links the innate and adaptive
immune systems is the dendritic cell (DC). DCs are sentinel cells capable of capturing and
presenting antigens to lymphocytes via their major histocompatibility complex (MHC) cell surface
proteins. This process mainly occurs in the secondary lymphoid tissues, lymph nodes and the
spleen, and is essential for the initiation of the adaptive immune response.
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Adaptive immunity
The adaptive immune system, sometimes referred to as the acquired immune system, is
a more versatile means of defense, providing increased protection against subsequent
reinfection with the same pathogen. The adaptive immune system is composed of B- and Tlymphocytes, and is activated when the infection eludes the innate defense mechanism. These
lymphocytes have a greater accuracy than the cells of the innate immune system, and each
individual cell responds to a specific antigen present on bacteria, viruses, toxins or foreign
objects. The antigen is presented to the lymphocytes by antigen presenting cells via cell receptor
MHC. The induction of the adaptive immune system only becomes effective after several days of
infection, as this is the time required for antigen-specific T and B cells to locate their specific
foreign antigen, proliferate and differentiate into effector cells. After the infection succumbs, the
adaptive immune system creates an immunological memory to the specific pathogen, leading to
an enhanced response to subsequent infections to the same pathogen, the very pathway utilized
by vaccines [62, 66, 67].
Both B and T cells are derived from the same multipotent hematopoietic stem cells. T cell
progenitors migrate from bone marrow to the thymus where they develop into T cells, while B
cells develop in the bone marrow. It is during development that the cells undergo several
selective steps to prevent auto-reactivity to self-antigens. When the developed lymphocytes
leave the thymus and bone marrow, they enter the lymphatic system and are considered naïve
until they encounter their corresponding antigen. Once a naïve T (or B) cell recognizes the
antigen-bound MHC molecule via T (or B) cell receptors and co-receptors, they undergo clonal
expansion to rapidly replicate numerous effector cells with the identical antigen recognition
receptor. Although they are morphologically similar to one another until they are activated, B
and T cells perform different tasks in fighting infections. B cells are vastly important in humoral
immune responses, that is, those in the blood, whereas T cells are intimately involved in cellmediated immune responses [62, 67, 68].
Another central feature of adaptive immunity is the development of immunological
memory. This is a process where pathogens are “remembered” through long lived memory B and
T cells. When the body is re-exposed to the same antigen, these memory cells proliferate very
quickly, producing an immune response that is much faster and much more robust than the initial
response to the antigen [62, 66, 67].

1.4 Immuno-metabolism
Historically, immunology and metabolism have been studied separately, but there is
increasing evidence of the coupling of immune status to metabolism, and vice versa. A classical
observation is that during an immune response, there is often a significant loss of appetite
12

leading to loss of body weight, suggesting the existence of shared signaling pathways between
immune and endocrine systems. More mechanistic studies have shown that many hormones
influence immune functions, and similarly many cytokines and growth factors produced during
an immune response can have an impact on neuronal and endocrine systems within both a
healthy or diseased host [6, 69-75].
While innate and adaptive immunity defend against non-host, invasive pathogens, sterile
inflammation is an event that is triggered by a host physical, chemical or metabolic noxiae in the
absence of a microbial signal. These non-microbial signals are DAMPs and are sensed by different
PRRs. It is now accepted that accumulations of DAMPs, such as necrotic cells, extracellular ATP,
saturated fatty acids or free cholesterol crystals, are sensed by PRRs in macrophages which
trigger chronic low-grade inflammation [76, 77]. This activates complex inflammasomes, which
initiate a sterile inflammatory cascade response, resulting in the release of IL-1β and IL-18 [78].
Such a response is often seen in chronic energy excess and obesity. Sterile inflammation that
ensues over time either resolves the initial insult or leads to disease, including metabolic
syndrome and insulin resistance [79-83].
Emerging evidence indicates that immune and metabolic interactions control several
aspects of metabolic syndrome, aging and chronic diseases. Thymic demise represents a
particularly interesting immune-metabolic interaction. Even in metabolically healthy, middle
aged individuals, the thymus involutes with deposition of ectopic lipids [84, 85]. In fact, the aging
alone is connected with immune-senescence, degeneration of the immune system that is
characteristic of a greater susceptibility to infections [86, 87], an inadequate immune response
to vaccinations [88, 89] and an increased propensity for autoimmune diseases and cancers [90,
91]. Why and how this occurs remains unresolved. Adipose tissue represents another important
site of immune-metabolic crosstalk. It acts as an endocrine organ that not only receives input
from other metabolic tissues, but also transmits signals in the form of adipokines, or adipose
derived hormones, that act locally and systemically to regulate nutrient balance.
Adipose tissue is now accepted as being heavily influenced by different facets of the
immune system, which in turn profoundly affects systemic metabolism [6, 75, 92]. There is
ongoing interest in this interaction and much is left to be discovered. Various cell populations of
both the innate and adaptive arms of the immune system can resist or exacerbate the
development of chronic, low-grade inflammation associated with obesity and metabolic
dysfunction [81, 93-95].
Recent studies have shown that metabolic neuro-endocrine peptides and adipokines also
control certain aspects of the immune system. This is evident by leptin’s ability to affect thymic
homeostasis and to act as a proinflammatory cytokine promoting Th1 cell differentiation [96].
There are also reports showing that leptin directly stimulates the expression and release of IL-1α,
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IL-1β, IL-6 and TNF-α from both monocytes and T cells [97]. Another example is ghrelin, the
endogenous ligand for the growth hormone secretagogue receptor, which has recently been
described to be a potent anti-inflammatory mediator both in vitro and in vivo, and a promising
therapeutic agent in treatment of inflammatory diseases and/or injury [98]. Interestingly, these
two hormones have important, yet opposite, effects on energy metabolism and inflammation.
Obesity-induced inflammation in adipose tissue and insulin resistance
Obesity-induced inflammation is closely associated with the development of metabolic
complications such as insulin resistance and type 2 diabetes [22]. Several immune-signaling
receptors and their counterpart ligands are known to be crucial for crosstalk between the innate
and adaptive immune system and metabolic pathways. Indeed, the metabolic syndrome is
associated with multi-organ inflammatory abnormalities (involving pancreatic, adipose, hepatic,
and cardiac and muscle tissue) and represents a major disease burden. TNF-α and IL-1β are
postulated to have a negative role in the pathogenesis of many metabolic disorders, as reflected
by the testing of a recombinant IL-1 receptor antagonist for the treatment of patients with type
2 diabetes [99].
Adipose tissue in rodents and humans is composed of different “types” of fat. They can
be compartmentalized into two main categories: visceral adipose tissue (VAT) and subcutaneous
adipose tissue (SAT). Accumulation of VAT is associated with insulin resistance and a high risk for
the development of the metabolic syndrome and type 2 diabetes. Conversely, accumulation of
SAT has been shown to have a possible protective effect against these metabolic abnormalities,
especially when distributed in the gluteo-femoral region of the body (lower body obesity). In
obese individuals, VAT has a higher percentage of large adipocytes and greater numbers of
inflammatory cells when compared to SAT [100, 101]. High fat feeding increases the numbers of
adipocyte precursor cells and mature adipocytes in both VAT and SAT. Similar to increases in
adipocytes, non-adipocyte precursor cells, such as stromal vascular cells, also increase in high fat
feeding conditions. Although this stromal vascular fraction shows dramatic increases in VAT after
2-4 weeks of a high fat diet (HFD), this is not seen as dramatically in SAT [102]. It is also now
accepted that mice fed HFD recruit both innate and adaptive immune cells in their adipose tissue
as they gain weight [103, 104]. Adipose tissue leukocytosis and chronic inflammation is now
accepted to play a profoundly deleterious effect on the pathogenesis of obesity induced
metabolic syndrome and type 2 diabetes.
Stephens and Pakala (1991) showed that the proinflammatory cytokine TNF-α was
sufficient to elicit a phenotype of insulin resistance by repressing GLUT4 and transcription factors
C/EBP family in 3T3-L1 adipocytes [75]. Hotamisligil et al further made early connections between
obesity, inflammation and insulin resistance, reporting an induction of TNF-α in adipose tissue
from four rodent models of obesity and diabetes. They went on to demonstrate that neutralizing
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TNF-α in obese rats ameliorated insulin resistance [6, 92]. Since this finding, follow up studies
have shown that alterations in the immune system during chronic over nutrition can result in
low-grade inflammation, which favors the development of insulin resistance [21, 105]. Similar to
studies in rodents, obese individuals with excess adipose tissue show increased circulating levels
of the proinflammatory marker C-reactive protein. Moreover, increased levels of C-reactive
protein, IL-6, and IL-1β are predictive of the development of type 2 diabetes in various
populations [106].
In summary, it is now evident that obesity triggers the accumulation of immune cells,
mostly macrophages, in the adipose tissue resulting in local sterile inflammation and ultimately
systemic insulin resistance.

Figure 1.4: Adipose tissue expand during obesity in parallel to inflammation and metabolic
dysregulation
Excess energy leads to adipose tissue expansion by both hypertrophy (larger adipocytes) and hyperplasia (more
adipocytes). With these hypertrophic adipocytes comes secretion of chemoattractant, leading to adipocyte
leukocytosis. Increases in activated immune cells results in increases in proinflammatory cytokine secretion. This
results in polarization of macrophages to a proinflammatory M1 phenotype and drives inflammatory lymphocyte
infiltration. Augmented lipolysis leads to increased levels of free fatty acids. This micro-environment negatively
impacts the insulin signaling pathway and leads to an insulin resistant state and dysregulated glucose homeostasis.
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Type I interferons, inflammation and glucose metabolism
Interferons (IFN) are a group of polypeptides that have antiviral, anti-proliferative,
cytostatic, antitumor and immunomodulatory effects on the innate and adaptive immune
response [107, 108]. IFNs cause changes in cell membranes, enzyme metabolism and protein
synthesis. Awareness of the existence of more than one type of IFN advanced progressively as a
result of the molecular cloning of the different IFN genes. Since the first published description of
IFN [109, 110], there has been an explosive growth in our understanding of genes encoding the
IFNs and their receptors, their complex signaling cascades and regulation, and their biological
activities [111]. IFNs are typically classified as Type I (IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω) and
Type II interferons (IFN-γ), and more recently Type III interferons [112]. There has recently been
an increase in scientific and clinical interest in elucidating the biology of type I interferons, which
began approximately 60 years ago with the discovery of interferons and concept introduced by
Jean Lindenmann of “viral interference,” a property that reduces the ability of a virus to infect
cells [109, 110].
Type I interferon is a sophisticated early defense mechanism positioned to combat
microbial infections and assist in the initiation of the adaptive immune response. By evolutionary
selection, the multiple type I IFN species evolved to signal through the same IFN-α/β receptor.
The interferon alpha gene cluster consists of 14 IFN-α homologous genes in mice and 13 in
humans, as well as one IFN-β gene. The evolutionary similarities of type I IFN among many animal
species attests to the necessity of type I interferon response for survival. The function of these
various species and the need for their differing physical profiles, receptor affinities and
downstream gene activation/silencing capabilities is, however, largely unknown. Type I
interferon is now a common therapy for autoimmune and inflammatory disorders, yet the
mechanism of its action remains poorly understood.
In the last decade, particular attention has been paid to the anti-inflammatory effects
exerted by type I IFN [113, 114]. A number of studies have shown the effectiveness of this family
of cytokines in reducing inflammation in different experimental settings. Most importantly, type
I IFN is successfully used in the clinic not only for the treatment of diseases of viral origin, but also
for managing diseases such as arthritis and multiple sclerosis [115-119]. Recently, evidence has
shown that type I interferon is an inhibitor of IL-1β production and inflammasome activation
[120]. Type I interferon signaling, via the STAT1 transcription factor, represses the activity of the
NLRP3 inflammasomes, and thereby suppresses caspase-1 dependent IL-1β. It has further been
shown that type I IFN treatment in monocytes obtained from patients with multiple sclerosis
leads to the production of substantially less IL-1β than monocytes derived from healthy donors.
In addition to the ability of type I interferons to inhibit the production of proinflammatory
cytokines, several papers suggest that type I interferons influence metabolic responses both
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centrally and peripherally. Studies show that IFN-α could have regulatory effects on body
temperature and food intake [121, 122]. Furthermore, there is evidence that IFN-β induces
glucose uptake in cells [123]. More specifically, evidence suggests a biphasic IFN-β-inducible
uptake of glucose by cells, mediated by phosphatidylinositol 3-kinase (PI3K)/Akt, and IFN-βinducible regulation of GLUT4 translocation to the cell surface. This data reveals that type I
interferons regulate glucose metabolism mediated by signaling effectors in a manner similar to
insulin. Furthermore, a commonly prescribed diabetic drug, metformin, enhances antiviral
effects of type I interferon during infection, suggesting a clear necessity for glucose
availability/utilization and proper immune response.

1.5 Nucleobindin-2
Nucleobindin (Nuc) was first identified in B-lymphocyte cell lines and is proposed to have
DNA binding domains, suggesting it may function as a transcription factor [124]. Nucleobindin is
a Golgi-resident protein that plays a key role in calcium homeostasis in the Golgi network [125].
Nucleobindin-2, or NUCB2/NEFA (for DNA binding/EF-hand/acidic protein), is a calcium binding
protein which also contains nuclear targeting signals, 2 helix-loop-helix regions with 2 concurrent
EF-hand motifs and a leucine zipper motif [126] (Figure 1.6). More recently, Nucb2 has been
shown to be present in the endoplasmic reticulum and in mitochondria [127]. NUCB2 is encoded
on chromosome 7F1, containing 14 exons in mice (chromosome 14 in human) with a genomic
sequence of 36,186 bps. Post transcription modifications leads to an mRNA sequence of 1,697
bp with a 420 amino acid long polypeptide. This polypeptide then undergoes posttranslational
modifications and is cleaved into three peptides termed nesfatin-1, nesfatin-2 and nesfatin-3
(Figure 1.5).
Nesfatin-1, the 82-amino acid peptide derived from Nucb2, was first described in 2006 to
be a regulator of food intake and energy expenditure [14] via regulation of the melanocortin
signaling pathway in hypothalamic nuclei. In 2008, it was further shown to have a much wider
distribution in the brain [128]. Daily intra-cerebroventricular (i.c.v.) injection of nesfatin-1
decreased food intake in a dose-dependent manner, whereas injection of an antibody
neutralizing nesfatin-1 stimulated appetite [14]. Moreover, under starved conditions, its
expression was decreased in the hypothalamic paraventricular nucleus. Chronic i.c.v. injection of
nesfatin-1 reduce body weight, whereas rats gain body weight after chronic i.c.v. injections of an
antisense morpholino oligonucleotide against the gene encoding NUCB2, leading the authors to
conclude that nesfatin-1 is a potent satiety signal and anorexigenic peptide hormone with
potential clinical applications in obesity treatments [14, 129-131].
Intriguingly, more recent experimental evidence suggests that NUCB2/nesfatin-1 is
ubiquitously expressed in peripheral tissues including the pancreas, adipose tissue, liver, kidney
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and the gut, in addition to the brain [132-134]. Such distribution implies that NUCB2/nesfatin-1
has important metabolic as well as immunologic functions. Recent reports indicate that Nucb2,
or nesfatin-1, also plays important roles in physiological processes beyond the control of feeding.
For example, two studies suggest that nesfatin-1 is involved in glucose homeostasis,
gastrointestinal function, water intake, temperature regulation and sleep [135, 136]. These
pleiotropic actions emphasize the physiological relevance of Nucb2 and/or nesfatin-1 to
metabolism. However the mechanisms underlying the involvement of these proteins in whole
body metabolism are still unknown.
Darambazar et al (2015) recently showed that treatment with leptin in vivo and in vitro
markedly increased Nucb2 mRNA expression in the paraventricular nucleus of the hypothalamus
(PVN), a brain region with critical roles in the control of ingestive behavior. The authors further
went on to show that peripheral and central injections of leptin failed to significantly inhibit food
intake in mice receiving adeno associate virus (AAV)-NUCB2. These results indicate that PVN
NUCB2/nesfatin-1 is directly targeted by leptin, and mediates its anorexigenic effect [137]. More
recent studies reported positive correlations in hypothalamic Nucb2 mRNA expression and serum
leptin levels in rats [138]. Moreover, Nucb2 expression in white adipose tissue is thought to be
regulated by the hypothalamus via the sympathetic nervous system [133]. In addition to these
findings, others showed that nesfatin-1 crosses the blood-brain barrier [139, 140] and that
peripheral administration of nesfatin-1 can decrease food intake in mice [23].
These initial findings provoked much excitement among groups studying obesity and
energy metabolism. An important and unresolved question, however, is whether altered
nesfatin-1 or Nucb2 activity in the hypothalamus contributes to insulin resistance in obesity.
Conditional in vivo targeting of Nucb2 to different brain regions or peripheral tissues would also
be informative of function, however technical challenges arise as nesfatin-1, nesfatin-2 and
nesfatin-3 might play differing functions yet are encoded by the same gene. Finally, the nesfatin1 receptor remains unknown, making studies determining precise sites of peptide action difficult.
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Figure 1.5: Graphical representation of Nucleobindin-2 gene, transcript and proteins
Nucb2 is transcribed from a 14 exon, 36,186 base pair sequence to a 1,697 mRNA sequence. It is initially translated
into a 420 amino acid molecule, comprising a signal peptide and Nesfatin-1,-2 and -3 sequence. The signal peptide
(24aa’s) is removed from the amino terminus. Nesfatin-1, -2 and -3 can then be post-translationally proteolytically
cleaved to form the 3 derivative peptide products.

Figure 1.6: Post translational peptide proteins and peptide motifs
Nucleobindin-2 peptide cleaved domain structure. Nesfatin-1 and Nesfatin-2 have leucine and isoleucine rich
regions. Nesfatin-3 contains a DNA binding domain (DNA), two helix – loop – helix EF-hand domains (EF-1 and EF-2),
a leucine zipper motif (LZ) and a C-terminal domain (C-term).

After this overall introduction to the importance of an immune-metabolic axis in
metabolic health, I will now describe in the next 3 chapters the experiments that I designed and
performed to assess the impact of nucleobindin-2 (Nucb2) and Nesfatin-1 on metabolic pathways
and metabolic health. The final chapter will be a discussion of the experiments conducted and
how they fit within scientific literature on immune-metabolic interactions with some suggested
future studies to better understand the field of immune metabolism.
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Chapter 2: Effects of Nucleobindin-2 on Glucose Homeostasis and Insulin
Resistance
2.1 Introduction
As previously mentioned in Chapter 1 above, prior studies have found that Nucb2
pharmacologically decreases food intake by regulating melanocortin signaling in the
hypothalamus [14]. Moreover, nesfatin-1 has recently been reported to be dramatically
upregulated and secreted into the culture media during the differentiation of 3T3-L1
preadipocytes into adipocytes [134]. This group further showed that treatments with TNF-alpha,
IL-6, insulin, and dexamethasone also increased nesfatin-1 secretion. In addition, circulating
nesfatin-1 levels were higher in high-fat-fed obese mice and showed positive correlation with
body mass index in humans. These studies induced our interest in the Nucb2 gene.
Additionally, several studies have recently suggested positive correlations in plasma
nesfatin-1 levels in patients with T2D and is associated with BMI, plasma insulin, and insulin
resistance [141-144]. Yang et al. recently indicated that infusion of nesfatin-1 into the third
cerebral ventricle markedly inhibited hepatic glucose production, promoted glucose uptake and
was accompanied by decreases in hepatic mRNA and protein expression of PEPCK in both chow
and HFD fed rats [144]. Fascinatingly, they went on to show that nesfatin-1 increased insulin
receptor, IRS-1, AMPK, and Akt and resulted in an increased Fos in the hypothalamus that
mediated glucose homeostasis.
Furthermore, we have observed that Nucb2 is highly expressed in cells of both innate and
adaptive immune system, but the function of this gene in immune-response or obesityassociated metabolic dysfunction is still largely unknown (Figure 2.6). In light of the fact that
injections of nesfatin-1 create an anorexic phenotype, we hypothesized that a complete genetic
knockout of Nucb2 would have an opposing effect and would lead to hyperphagia and obesity.
We also were interested in determining if Nucb2 directly interfered with insulin signaling. We
also sought to determine the causal and physiological role of Nucb2 in the regulation of immunemetabolic crosstalk and inflammation in vivo. In order to do so we generated a Nucb2 floxed
allele by introducing a PL253-loxP-frt-neo cassette to exon 3. We initially created a global
knockout by crossing floxed Nucb2 founder C57Bl/6 mice with a global Ella-Cre driver to remove
the floxed sequence (Figure 2.3, Figure 2.4, and Figure 2.5). Overall, the most striking phenotype
in the mice lacking Nucb2 is significant impairments in insulin sensitivity and glucose homeostasis
in high fat fed-induced obesity.
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2.2 Materials and Methods
Mice and animal care
Mice were generated with the transgenic core at Pennington Biomedical Research Center by Dr.
Randall Mynatt and kept in a pathogen-free barrier facility maintained at 22–24°C with a 12:12h dark-light cycle (lights on at 0700 h). Initial genotyping was done with help by Dr. Bolormaa
Vandanmagsar. Mice were housed up to 5 per cage and given ad-libitum access to normal chow
(#5002, at least 4.5% kcal crude fat, LabDiet), low fat diet (LFD; #D12450B, 10% kcal as fat,
Research Diets, New Brunswick, NJ) or a high fat diet (HFD; #D12492i, 60% kcal as fat; Research
Diets, New Brunswick, NJ) and sterilized water (Hydropac Alternative Watering System: Seaford,
DE, USA). The mice were placed on the LFD or HFD at 6 weeks of age and maintained on it until
death. All transgenic and WT mice were cross-fostered to parent cohorts in our colony. The
sentinel mice in our animal rooms were negative for currently tested standard murine pathogens
(ectromelia, epizootic diarrhea of infant mice [EDIM], lymphocytic choriomeningitis [LCMV],
Mycoplasma pulmonis, mouse hepatitis virus [MHV], murine norovirus [MNV], mouse parvovirus
[MPV], murine minute virus [MVM], pneumonia virus of mice [PVM], reovirus type 3 [REO3],
Theiler's murine encephalomyelitis virus [TMEV], and Sendai virus) at various times while the
studies were performed. Changes in body weights were measured during the life of the animals.
Fat mass (FM) and fat free mass were assessed by time-domain-nuclear magnetic resonance
(Minispec Analyst AD; Bruker Optics, Silberstreifen, Germany) at different time points.
Hyperinsulinemic-euglycemic clamp
Clamp studies were performed according to recommendations of the Mouse Metabolic
Phenotyping Center Consortium [145]. The clamp studies were performed on 14 week old, chowfed mice, and on 12 week old mice (n=8 wild type, n=7 Nucb2 -/-) on a high fat diet for 6 weeks
(n=11 wild type, n=7 Nucb2 -/-). After surgical implantation of an indwelling catheter in the right
jugular vein, mice were allowed to recover for 7 days prior to the clamp experiments. Following
an overnight 14-h fast, mice were infused with 3-[3H] glucose (HPLC purified; PerkinElmer Life
Sciences, Waltham, Massachusetts) at a rate of 0.05 μCi/min for 120 min to determine basal
glucose turnover. Next, a primed infusion of insulin and 3-[3H] glucose was administered for 4
min at rates of 7.14 milliunits·kg−1·min−1 and 0.24 μCi/min, respectively, after which the rates
were reduced to 2.5 milliunits·kg−1·min−1 insulin for chow fed mice/3 milliunits·kg−1·min−1
insulin for HFD mice (Novolin; Novo Nordisk, Bagsværd, Denmark) and 0.1 μCi/min 3-[3H] glucose
for the remainder of the experiment. Plasma samples were obtained from the tip of the tail at 0,
25, 45, 65, 80, 90, 100, 110, 120, 130, and 140 min for plasma glucose, insulin, and tracer levels.
A variable infusion of 20% dextrose was given to maintain euglycemia (100-120 mg/dL). Also,
mice received an i.v. albumin-containing solution mimicking artificial plasma (115 mM NaCl, 5.9
mM KCl, 1.2 mM MgCl2-6H2O, 1.2 mM NaH2PO4-H2O, 1.2 mM Na2SO4, 2.5 mM CaCl-2H2O, 25 mM
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NaHCO3, and 4% BSA [pH 7.4]) at a rate of 4.2 μL/min, during the insulin-stimulated period of the
clamp to compensate for volume loss secondary to blood sampling.
Glucose turnover was calculated as the ratio of the 3-[3H] glucose infusion rate to the
specific activity of plasma glucose at the end of the basal infusion and during the last 40 min of
the hyperinsulinemic-euglycemic clamp study. Hepatic glucose production represents the
difference between the glucose infusion rate and the rate of glucose appearance. A 10-μCi bolus
injection of 2-deoxy-d-[14C]-glucose was given at 90 min to determine tissue-specific glucose
uptake, which was calculated from the area under the curve of 2-deoxy-d-[14C]-glucose detected
in plasma and the tissue content of [14C]2-deoxyglucose-6-phosphate, as previously described
[146]. Following collection of the final blood sample, mice were anesthetized with an intravenous
injection of 150 mg/kg pentobarbital, and tissues were harvested and frozen with aluminum
forceps in liquid nitrogen. All tissues were stored at −80 °C until later use.
Serum hormones and metabolite profiles
Blood was collected from all mice by cardiac puncture following CO2 administration. Blood
collected from mice was allowed to clot at 22°C for 2-h before centrifugation at 2,000g for 20 min
at 4°C. Serum was kept at -80°C until assays were performed. All assays were performed in
accordance with the provided standard operated procedures. Insulin levels were measured using
the Mercodia Ultrasensitive Mouse Insulin ELISA (Mercodia; Uppsala, Sweden). Adiponectin was
measured using Mouse Adiponectin ELISA kit (EMD Millipore; St. Charles, Missouri, USA). Leptin
was measured using Mouse/Rat Leptin Quantikine ELISA (R&D Systems; Minneapolis, MN, USA).
IL-18 was measured using MBL mouse IL-18 ELISA (Medical & Biological Laboratories; Nagano,
Japan). Nesfatin-1 was measured using nesfatin-1 (1-82aa) (rat) EIA kit (EK-003-22; Phoenix
Pharmaceuticals; Burlingame, CA, USA) with a detectable range of 0.1-1000ng/ml. Nucb2 was
measured using mouse Nucleobindin-2 (NUCB2) ELISA kit (CUSABIO; Wuhan, Hubei Province, P.R.
China) with a detectable range of 15.6-1000 pg/ml. For the nesfatin-1 and Nucb2 assays, some
sample diluent was spiked with nesfatin-1, nesfatin-2 and nesfatin-3 recombinant protein at
concentrations of 100 nM (Phoenix Pharmaceuticals; Burlingame, CA, USA). Blood glucose was
detected using Breeze2 Blood glucose test strips (Bayer HealthCare; Mishawaka, IN, USA) via tail
bleed.
Tissue digestion and positive selection of T cells and macrophages
Adipose tissue was digested using enzymatic digestion as previously described [147].
Adipose tissue stromal vascular fraction cells were then collected, and T cells and macrophages
were positively selected using CD3 and F4/80 labeled antibodies (Dynabeads, Life Technologies).
Quantitative PCR
RNA from tissue and cells was isolated using an RNeasy Plus mini and micro kit (Qiagen;
74106 and 74034) according to the manufacturer's instructions. DNA digestion was performed
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on the columns to remove DNA using RNase-Free DNase according to manufacturer's instructions
(79254; Qiagen). Following RNA purification, samples were then used for iScript cDNA synthesis
using a reverse transcriptase PCR kit (BIO-RAD; Hercules, CA, USA). Quantitative PCR was
performed with the LightCycler 480 II (Roche Applied Science; Indianapolis, IN, USA) and Power
SYBR Green detection reagent (Applied Biosystems by Thermo Fischer Scientific; Woolston
Warrington, UK). Primer sequences for transcripts encoding proteins involved in lipid and glucose
metabolism were designed with Primer Express Software. For Nucb2, we used the forward primer
5'-AAAACCTTGGCCTGTCTGAA-3' and the reverse primer 5'-CATCGATAGGAACAGCTTCCA-3'. In all
qRT-PCR experiments, 25 ng cDNA was used. Fold induction of gene expression with Nucb2 was
analyzed with the ΔΔCt method (also known as the comparative Ct method) as determined by
the following equation: ΔΔCt = ΔCt treatment (age and diet) - ΔCt control (young/chow). Here,
the ΔCt is the Ct value for the sample (Nucb2) normalized to the endogenous housekeeping gene
GAPDH transcript.
Tissue Hematoxylin and Eosin (H&E) staining
The adipose tissue and liver were collected from mice, fixed in 4% (vol/vol) buffered
paraformaldehyde, embedded in paraffin and optimal cutting temperature (OCT) compound,
then cut into 5 μm thick sections. Tissue sections were stained with hematoxylin and eosin (H&E).
Fluorescent images of H&E-stained paraffin-sections were photographed using the Texas Red
filter cube on an Axioplan 2 imaging microscope (Carl Zeiss Microscopy; Thornwood, NY, USA).
Quantification of adipocyte size was measured using ImageJ image analysis software. The
averages were found by measuring 15 adipocytes from 3 different sections from 4 different mice
per group.
Statistical analysis
We used a two-tailed Student's t-test to examine differences between genotypes or
treatments (age and feeding) with a P < 0.05 considered statistically significant. The results are
expressed as the arithmetic means ± SEM. Differences between means and different genetic
model were determined by one-way ANOVA using Tukey's test, using SigmaStat or Graphpad
Prism software, which protects the significance (P < 0.05) of all pair combinations.

2.3 Results
Nucb2 gene expression in immune cell subsets is regulated by diet
We first sought to understand if Nucb2 expression was related to either age and/or diet
composition. We performed qRT-PCR using 12.5 ng cDNA to measure mRNA levels of Nucb2 from
3 month and 6 month old wild type mice either on low fat diet or a high fat diet (n=6 per group).
There were no significant differences in Nucb2 expression levels due to age or diet in the
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hypothalamus, visceral adipose tissue, and in liver (Figure 2.1). Inguinal adipose tissue on the
other hand, showed differences in Nucb2 expression. At age 3 months, HFD increased Nucb2
expression levels (LFD and HFD: 1 ± 0.03 and 3.04 ± 0.51, respectively, p=0.003); however HFD
had no differences in Nucb2 expression levels at 6 months of age (LFD and HFD: 1.39 ± 0.38 and
0.92 ± 0.24 respectively, p=0.31). A decrease in Nucb2 expression levels was observed with aging
(3 month and 6 month: 3.04 ± 0.43 and 0.92 ± 0.24, respectively, p=0.001) only on a HFD (Figure
2.1).
In the pancreas, we saw significant changes in Nucb2 gene expression in response to
aging. HFD mice had a trend towards a decrease in Nucb2 expression levels at both 3 and 6
months of age; however, this was not significant (3 month LFD and HFD: 1 ± 0.12 and 0.63 ± 0.12,
p=0.06 respectively and 6 months LFD and HFD: 0.42 ± 0.06 and 0.28 ± 0.05 respectively, p=0.12)
(Figure 2.1). Aging, on the other hand, induced a significant decrease in pancreatic Nucb2
expression levels in both LFD (3 month and 6 month: 1.0 ± 0.12 and 0.42 ± 0.063, respectively,
p=0.003) and HFD (3 month and 6 month: 0.629 ± 0.12 and 0.28 ± 0.05, respectively, p=0.02).
This suggests Nucb2 expression is downregulated in aging and obesity.
Interestingly, diet composition regulated the expression of Nucb2 in both macrophages
and T lymphocytes isolated from adipose tissue. Positively selected macrophages from visceral
adipose tissue showed a significant increase in Nucb2 expression in HFD mice aged 3 months (LFD
and HFD: 1.0 ± 0.19 and 6.08 ± 1.35, respectively, p=0.04) and 6 months (LFD and HFD: 2.47 ±
0.24 and 7.31 ± 0.9, respectively, p=0.007) (Figure 2.2). Additionally, purified T cells from visceral
adipose tissue displayed an increase in Nucb2 expression levels in HFD mice aged 3 months (LFD
and HFD: 1.0 ± 0.06 and 1.81 ± 0.13, respectively, p=0.003) and 6 months (LFD and HFD: 0.70 ±
0.10 and 1.38 ± 0.11, respectively, p=0.006) (Figure 2.2).
Overall, HFD stimulates increased expression of Nucb2 in isolated macrophages and T
cells from visceral adipose tissue. HFD also significantly increases Nucb2 expression in 3 month
old mice; however, this is not seen at 6 months of age. Nucb2 in the pancreas, on the other hand,
is significantly reduced by age in both chow conditions and HFD conditions. It is unclear, however,
if these changes are a result of the diet composition directly, or obesity and weight gain.
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Figure 2.1: Age and diet modulates Nucb2 expression differently in different tissues
Relative Nucb2 gene expression (mRNA) levels were measured by quantitative RT-PCR. Values are expressed as fold
change means ± S.E.M., with mean expression in 3 month old LFD as control (n=6 per group). (A) Hypothalamus (B)
Liver (C) Visceral Adipose Tissue (D) Inguinal Adipose Tissue (E) Pancreas. *p< 0.05, **p<0.005.
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Figure 2.2: High fat diet-induced obesity increases Nucb2 expression in visceral adipose tissue
macrophages (ATMs) and T cells
Relative Nucb2 gene expression (mRNA) levels were measured by quantitative RT-PCR from positively selected
macrophages (F4/80+) and T cells (CD3+). Values are expressed as fold change means ± S.E.M., with mean expression
in 3 month old LFD as control (n=6 per group). (A) Visceral Adipose Tissue Macrophages (B) Visceral Adipose Tissue
T Cells. *p< 0.05, **p<0.005.
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Nucb2 target sequence, vector construct, genotyping, and creation of a global Nucb2 -/mouse
Combined with prior studies suggesting strong effects of nesfatin-1 on energy intake and
body composition, our findings that Nucb2 is highly expressed in both innate and adaptive
immune cell subtypes and is regulated by diet lead us to hypothesize that Nucb2 may play
important roles in immune-metabolic interactions. The function of this gene in immune-response
or obesity-associated metabolic dysfunction, however, is still largely unknown (Figure 2.6). We
thus sought to create a Nucb2 knockout mouse to examine its function in the context of immunemetabolic function. Considering injections of nesfatin-1 create an anorexic phenotype [14], we
reasoned a complete knockout would have an opposing effect and lead mice to be hyperphagic
and become obese.
We used a genetic targeting approach to investigate the physiological role of Nucb2 in the
regulation of immune-metabolic crosstalk, and in inflammation in vivo. We did this by generating
a Nucb2 floxed allele by recombination of a PL253-loxP-frt-neo cassette to exon 3 in mouse
embryonic stem cells (
Figure 2.3). These mice were created by the Pennington Biomedical Research Center
transgenic core with Dr. Randy Mynatt using established technology described in herein. Once
our vector was correctly designed and screened against neomycin for initial enrichment of the
targeted clone, we used these embryonic stem cells for injection into blastocysts for the
generation of heterozygous Nucb2-loxP floxed mice. These positive ES cells were used. Using
polymerase chain reaction to genotype these neo-founder mice (Figure 2.4), we then removed
the neomycin resistant drug marker by crossing to a recombinase FLP derived mouse which
recognizes the flippase recognition target (FRT) for mediated cleavage and generation of our
founder mice (Figure 2.5). We initially created a global knockout by crossing floxed Nucb2
founder C57Bl/6 mice with a global Ella-Cre driver to remove the floxed sequence.
We initially confirmed expression of Nucb2 in immune cell subsets (B cells, T cells and
macrophages) as well as different adipogenic stages of adipocyte differentiation as well as
astrocytes and microglia using RT-PCR (Figure 2.6). In parallel, we confirmed successful ablation
of Nucb2 from all analyzed tissues obtained from 12-week old Nucb2 -/- mice.
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Figure 2.3: Nucb2 -/- vector construct and embryonic stem cell PCR screens
Vector design depicting the genomic region surrounding exon 3 with the Neo construct. (A) Original BAC clone of
wild type allele genomic region. (B) Nucb2 knockout strategy with PL253-loxP-frt-neo cassette flanking exon 3. Frt is
the flippase recognition target and Neo is removed using Flp recombinase once screened for neomycin resistant
strains cells. The Nucb2 loxP flanked allele is then removed using a Cre-mediated recombinase. (C) PCR product of the
loxP flanked allele. Primers were designed for the 5’ loxP site with a 3.1kb allele confirming insertion of the loxP
allele. Primers were also designed for the 3’ loxP site with a 4.3kb allele size (done with help by Dr. Bolormaa
Vandanmagsar).
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Figure 2.4: Nucb2 floxed-neo/+ founder mouse and PCR genotyping screen
Genomic targeting diagram depicting region surrounding exon 3 with the Neo construct shown in the diagram. (A)
Nucb2 knockout strategy with PL253-loxP-frt-neo cassette flanking exon 3. Frt is the flippase recognition target and
Neo is removed using Flp recombinase once screened for neomycin resistant cells. (B) 5’ PCR product of the Nucb2floxed Neo/+ founder mouse (C) 3’ PCR product of the Nucb2-floxed Neo/+ founder mouse. Red boxes confirm the
correct genotyping of our Nucb2-neo/+ founder mice.

Figure 2.5: Nucb2-floxed/+ founder mouse and PCR genotyping screen
Genomic targeting diagram depicting region surrounding exon 3 with the Neo construct removed shown in the
diagram. (A) Nucb2 knockout strategy with PL253-loxP flanking exon 3. Neo is removed using Flp recombinase once
screened for neomycin resistant cells. (B) 5’ PCR product of the Nucb2-floxed founder mouse (C) 3’ PCR product of
the Nucb2-floxed founder mouse. Red boxes confirm the correct genotyping of our Nucb2-floxed+/- founder mice.
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Figure 2.6: Nucb2 is ubiquitously expressed in many cell types and tissue
Relative Nucb2 gene expression (mRNA) levels were measured by quantitative RT-PCR. Values are expressed as
relative means ± S.E.M. (n=4 per group). (A) Relative Nucb2 expression in different cell types. There is a high
expression of Nucb2 in B220 B cells, CD3 T cells and F4/80 macrophage positive cells. (B) Relative Nucb2 expression
in different tissues. There is a high Nucb2 expression level in metabolic tissues (adipose tissues, pancreas and
pituitary) as well as in whole spleen.

Together, these data show the correct vector targeting of Nucb2 gene and that our
knockout mice are in fact void of the Nucb2 gene. This is evident by our inability to detect Nucb2
gene expression in all the tissues studied in our Nucb2-/- mice (Figure 2.6).
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Serum nesfatin-1/Nucb2 expression levels are unchanged and have no effect on food
intake and hypothalamic AgRP levels
Nesfatin-1 has been described as a potent regulator of food intake. Oh et al (2006) found
that i.c.v injections of nesfatin-1 decrease food intake by regulating melanocortin signaling in the
hypothalamus [14]. To determine the physiological response to the ablation of the Nucb2 gene,
we measured food intake as well as hypothalamic agouti-related peptide/protein (AgRP) levels,
as AgRP is a well characterized orexigenic peptide.
Surprisingly, there were no differences in serum nesfatin-1 levels (Figure 2.7) between
fed and fasted wild type mice, and fasted Nucb2-/- mice (WT fed, WT fasted and Nucb2 -/- fasted;
14.39 ± 10.06 ng/ml, 17.36 ± 7.97 ng/ml and 14.41 ± 10.26 ng/ml, respectively, p=0.3 and p=0.8).
Wild type and Nucb2 -/- mice fed a HFD also showed no difference in serum nesfatin-1 levels
(WT: 3.62 ± 0.38 ng/ml, and Nucb2 -/- 3.21 ± 0.09 ng/ml, respectively, p=0.4) (Figure 2.7). We
also ran parallel ELISAs for circulating levels of Nucb2 in the same groups of animals, and similarly,
saw no significant differences among any groups. There were no differences in Nucb2 levels
between fed or fasted WT mice, nor fasted Nucb2 -/- mice (WT fed, WT fasted and Nucb2 -/fasted; 665.8 ± 37.9 pg/ml, 598.5 ± 30.7 pg/ml and 578.5 ± 62.3 pg/ml, respectively, p=0.8 and
p=0.9). Under high fat conditions, we also saw no difference in Nucb2 levels between wild type
and Nucb2 -/- mice (710 ± 108.6 pg/ml and 610.4 ± 61.06 pg/ml, respectively, p=0.4) (Figure 2.7).
To further validate the specificity of nesfatin-1 as a secreted peptide derived from Nucb2,
we added known amounts of recombinant nesfatin-1, -2 and -3 at concentration of 100 nM and
tested the various commercial kits that have been reported in the literature. We did not see
nesfatin-1 or Nucb2 expression in control sample diluent with no serum but spiked with 100 nM
nesfatin-1, -2, and -3 recombinant protein (nesfatin-1 levels: 1.59 ± 0.12) (Nucb2 levels: 43.74 ±
5.6 pg/ml) (Figure 2.7). After further examination using recombinant protein as control, we
concluded that the ELISA kits are not specific. This is seen clearly between the negative blank
control and positive high dose (100 nM) of nesfatin-1, nesfatin-2 and nesfatin-3 spike control
(Figure 2.7). In addition, the commercial ELISA kits detected spurious levels of nesfatin-1 in mice
that lack the Nucb2 gene. These results question the existence of nesfatin-1 as physiologically
relevant peptide that derived from Nucb2.
We next examined the effect of Nucb2 on food intake and its effects of hypothalamic
AgRP responses. Food intake was measured daily over 3 days and averaged. There were no
significant differences in food intake between WT mice and Nucb2 -/- mice fed a chow, ad libitum
diet (3.54 ± 0.13 g and 3.65 ± 0.16 g respectively, p=0.6) (Figure 2.8). In concordance with chow
diet, there were also no differences between groups fed a HFD (2.8 ± 0.1 g and 2.65 ± 0.15 g
respectively, p=0.4) (Figure 2.8).
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Corroborating these findings, we saw no differences in hypothalamic AgRP levels between
WT and Nucb2-/- mice (WT and Nucb2-/-: 1.0 ± 0.1 and 1.07 ± 0.15 ΔΔCt fold change, respectively,
p=0.7) (Figure 2.8) on a HFD. As expected, AgRP levels significantly increased after a 24 hour fast
in both WT and Nucb2 -/- mice (2.51 ± 0.23 and 2.62 ± 0.4 ΔΔCt fold change in wild type and
Nucb2 -/- respectively, p=0.6) (Figure 2.8). Unlike previous reports of nesfatin-1 as a strong
regulator of food intake, this data shows that Nucb2 is not a physiologically important regulator
of food intake.
A

B

Figure 2.7: Nucb2 ablation does not alter detected circulating levels of nesfatin-1 or Nucb2
(A) There are no differences in Nesfatin-1 and NUCB2 levels between wild type fed and fasted, as well as fasted
Nucb2 -/- mice (n=6/group). When the sample diluent was spiked with high levels (100 nM) of recombinant nesfatin1, nesfatin-2 and nesfatin-3, there was no significant difference in detected levels as compared to the blank. (B) 10
month old, male mice on a high fat diet also had no differences in either nesfatin-1 or Nucb2 levels between wild
type HFD and Nucb2 -/- HFD (n=5/group).
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Figure 2.8: Nucb2 ablation does not alter food intake
Food intake was measured by mass over 72 hours every 12 hours and represented over a 24 hour average (chow,
n=8/group HFD, n=5-8/group). (A) There are no differences in cumulative ad libitum food intake over 24 hours
between 14 week old chow fed WT and Nucb2 -/- mice, nor between 10 month old HFD fed WT and Nucb2 -/- mice.
(B) As expected, fasting significantly increases hypothalamic AgRP levels in both WT and Nucb2 -/- mice (n=6/group).
On a high fat diet, there are also no differences in hypothalamic AgRP expression (n=5/group).

These data demonstrates that unlike previous reports [14], Nucb2 does not impact
feeding behavior in both chow fed and fasted mice and HFD fed mice, as well as hypothalamic
AgRP levels. We also measured levels of Nucb2 and Nesfatin-1 in periphery. However, our ELISA
Results showed no differences between the mice groups, as well as no differences between the
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blank samples and the sample diluent spiked with Nesfatin-1, Nesfatin-2 and Nesfatin-3
recombinant protein indicating that this commercial assay is not reliable.
Nucb2 has no effect on body weight and body composition
We next examined whether Nucb2 influences body weight and body composition in
animals fed both normal chow and HFD. There were no significant changes in body weight or
body composition, as assessed by proton NMR, between the WT and Nucb2-/- littermate mice in
both chow and high fat fed conditions. This was seen at various time points sampled throughout
the lifespan of the mice. Young, 14 week old WT mice fed a chow diet weighed 28.65 ± 0.55 (n=8)
and Nucb2 -/- mice weighed 30.06 ± 0.82g (n=7), p=0.2 (Figure 2.9). During ad libitum high fat
feeding, 12 week old wild type mice weighed 27.02± 0.6 (n=11) and the Nucb2-/- mice weighed
28.51 ± 0.63g (n=7), p=0.1 (Figure 2.9). Using proton NMR to measure differences in body
composition, we found no statistical differences in fat mass between wild type and Nucb2 -/mice. On the chow diet, wild type mice had 2.05± 0.14g of fat, whereas Nucb2 -/- mice had 1.86
± 0.44g of fat, p=04. On the high fat diet, wild type mice had 4.8 ± 0.4g of fat, whereas Nucb2 -/mice had 5.65 ± 0.5g of fat, p=0.2. We therefore conclude Nucb2 does not play a role in regulating
body weight or body composition in either chow or HFD conditions.
Moreover, to determine if Nucb2 had an effect on body weight and adiposity in the long
term (at an older age), we chronically fed high fat diet to WT and Nucb2-/- mice for 10 months.
Nucb2 -/- mice showed similar body weight and fat mass as the WT controls (WT HFD 52.25 ±
1.306g (n=8), Nucb2 -/- HFD mice weight 52.60 ± 1.12g, p=0.9 (n=5) (Figure 2.9). In addition to
having no differences in body weight, Nucb2 -/- mice also showed no differences in body mass
composition as compared to control (Figure 2.9). Visceral fat mass (1.41 ± 0.15 g and 1.34 ± 0.08
g, p=0.7), inguinal fat mass (2.49 ± 0.14 g and 2.1 ± 0.13 g, p=0.1) and perirenal fat mass (1.21 ±
0.06 g and 1.19 ± 0.06 g, p=0.8) were no different between WT control and Nucb2 -/- mice. This
data suggests Nucb2 is not involved in the maintenance of body weight or body composition in
either chow or high fat conditions.
To summarize, Nucb2 is not an important regulator of body weight nor body composition
during both chow fed and HFD conditions. We observe no differences in body weight nor body
composition between the wild type control groups when compared to littermate Nucb2-/- mice.
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Figure 2.9: Nucb2 ablation has no effect on body weight and body composition
(A) Body weight and body fat in grams of 14 week old chow-fed mice (WT n=8, KO n=7) and 12 week old HFD-fed
mice (WT n=11, KO n=7). (B) Body weight of 10 month old HFD-fed mice and different adipose tissue weights (WT
n=8, KO n=5).

Nucb2 has no impact on adipose tissue morphology, hypertrophy and hyperplasia
More than overall adipose tissue size (adiposity), both individual adipocyte size itself and
micro-environment are vital in normal glucose homeostasis and in the maintenance of glucose
disposal [148]. Further, an adipocyte’s inability to expand and store lipid in obese conditions is
associated with insulin resistance due to ectopic fat stores and lipid-spillover in liver and muscle
[149]. We thus sought to determine if knockout of Nucb2 gene induced changes in adipocyte size,
or in the morphology of adipose tissue. Histological appearances of the white adipose tissue are
shown in (Figure 2.10). Using hematoxylin and eosin (H&E) staining in a Texas red filter, we
observed no difference in adipocyte morphology. Further quantification showed no difference in
average adipocyte size between the wild type (6372 ± 200.3 um2) and Nucb2 -/- (5942 ± 204.0
um2) mice, p=0.1.
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Figure 2.10: Nucb2 ablation does not impact adipocyte morphology and adipocyte size
(A) Adipose tissue stained with H&E from 10 month old wild type and Nucb2-/- mice fed an ad libitum high fat diet
and photographed at x20 magnification. Scale bar = 100um. (B) The average size of adipocyte was measured by using
Image J and averaging over 180 different cells from 4 different mice/strain. (C) Size distribution histogram from 4
mice/group.
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Overall, these data demonstrate that there is no difference in adipose tissue morphology,
or adipocyte size between the wild type controls and Nucb2 -/- mice at 10 months obesity
induced high fat diet.
Serum metabolites and cytokines are mostly unaffected in Nucb2-/- mice
Next, we wanted to determine if Nucb2 has an effect on circulating peripheral metabolites
under different metabolic conditions. Yadav et al. (2013) showed that different circulating
cytokines, as well as adiponectin, which is inversely correlated with adipose tissue size, and
leptin, which is directly correlated to adipose tissue size, can potentially regulate insulin
resistance [150]. Analyses of metabolites and cytokines were performed for in different
experiments. The first experiment included 3 groups of 6 month old, male mice; wild type mice
fed an ad libitum chow diet or fasted for 24 hours, and Nucb2-/- 24 hour fasted mice (n=6/group).
The second experiment was performed on both wild type and Nucb2-/- HFD-fed 10 month old
male mice (n=5/group).
Since adiponectin has been shown to be inversely correlated with adipose tissue size, and
to mediate an insulin-sensitizing effect by binding to its receptors AdipoR1 and AdipoR2, we
wanted to see if ablation of Nucb2 affected adiponectin levels. First, we identified a trend
towards increasing adiponectin levels in fasted mice; however there was no difference in
adiponectin levels between wild type and Nucb2-/- mice in a fasted state (149 ± 6.1 and 150 ±
6.9, respectively, p=0.9). Under high fat conditions, we also saw no difference in adiponectin
levels between wild type and Nucb2-/- mice (151.1 ± 1.38 and 159.1 ± 4.59, respectively) (Figure
2.12).
In addition to a lack of effect of Nucb2 knockout on adiponectin levels, there were no
differences in circulating leptin levels between wild type and Nucb2 -/- mice both under fasting
conditions and HFD conditions. There was a significant drop in leptin levels after fasting (WT, fed
vs fasted: 2583 ± 419 pg/ml and 1229 ± 370 pg/ml respectively, p=0.04) and this was also seen in
Nucb2 -/- mice (Nucb2-/-, fed vs fasted: 2583 ± 419 pg/ml and 587.5 ± 450 pg/ml respectively,
p=0.001). We observed no difference in leptin levels between wild type and Nucb2 -/- fasted mice
(p=0.1). Furthermore, there were no differences in leptin levels between WT and Nucb2 -/- mice
fed a high fat diet (WT and Nucb 2-/-: 5068 ± 214 pg/ml and 5064 ± 286 pg/ml, respectively,
p=0.99) (Figure 2.12).
In addition to looking at circulating adipokines and metabolites, we also measured how
Nucb2 affects systemic peripheral cytokines. Changes in circulating cytokine levels have been
associated with many diseases; however, most cytokines circulate in peripheral blood in very low
concentrations and are very difficult to detect under sterile conditions. IL-18, on the other hand,
has been shown to have a constitutive pool and is thus easily measurable in serum. Furthermore,
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IL-18 has been reported to be an important insulin sensitizer [151]. We thus measured serum
levels of IL-18.
There was a trend towards a fasting-induced increase in IL-18 levels in wild type mice (WT
fed vs fasted: 622.5 ± 20.2 pg/ml and 731.3 ± 60.9 pg/ml respectively p=0.1), however, not
significant. We observed the opposite in Nucb2 -/- mice, where fasting induced a significant
decrease in IL -18 levels as compared to fasted wild type mice (WT vs Nucb2-/- fasted: 731.3 ±
60.9 pg/ml and 505.8 ± 42.7 pg/ml respectively, p=0.01) and also a decrease IL-18 in Nucb2-/mice compared to WT fed mice (p=0.03) (Figure 2.12). Furthermore, there was no significant
difference in IL-18 levels in wild type versus Nucb2 -/- mice fed a high fat diet (HFD-WT and HFDNucb 2-/-: 741.7 ± 66.9 pg/ml and 597.2 ± 37.8 pg/ml, respectively p=0.1) (Figure 2.12), despite
a decreasing trend in the Nucb2 -/- HFD mice.
A
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Figure 2.11: Nucb2 ablation does not affect circulating adipokines in HFD fed mice
(A) Adiponectin Levels are no different between wild type chow fed and fasted mice and Nucb2-/- fasted mice
(n=6/group), and between wild type and Nucb2 -/- HFD mice (n=5/group). (B) There is a decrease in Leptin levels
during fasting states in both wild type and Nucb2-/-, however, there is no significant difference between wild type
and Nucb2 -/- (n=6/group). There is an increase in Leptin levels of mice on a HFD, however, there is no difference
between wild type and Nucb2-/- (n=5/group).
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Figure 2.12: Nucb2 ablation does not affect circulating IL-18 in HFD fed mice
There is no difference between chow fed and fasted wild type mice, however, there is a slight decrease between
wild type fasted mice and Nucb2-/- fasted mice (n=6/group). There is a decreasing trend in the Nucb2-/- HFD mice
when compared to wild type, however this is not significant (n=5/group).

Overall, there does not seem to be a difference in levels of serum metabolic hormones
between the wild type mice and the Nucb2 -/- mice in different metabolic states. On the other
hand, Nucb2-/- mice have a significantly lower IL-18 expression in fasted mice, and a trend of
lower IL-18 levels in HFD Nucb2-/- mice.
Nucb2 does not regulate insulin signaling or glucose homeostasis in ad-libitum fed chow
mice
To test if Nucb2 is important in regulating metabolism and whole-body insulin action, we
performed euglycemic-hyperinsulinemic clamps on 14 week old mice fed ad libitum chow diets.
As described above, wild type (n=8) and Nucb2 -/- (n=7) mice had no significant differences in
body weight (28.65g ± 0.55g and 30.06g ± 0.82g respectively, p=0.2). Furthermore, there was no
difference in the fat mass between wild type and Nucb2 -/- mice (2.05 ± 0.14 and 1.86 ± 0.27
respectively, p=0.38).
Compared to wild type mice, Nucb2 -/- mice showed no differences in whole-body insulin
sensitivity. Indeed, compared to wild type mice, Nucb2 -/- mice required similar glucose infusion
rate to maintain euglycemia during the entirety of the hyperinsulinemic-euglycemic clamp
(Figure 2.13). There were also no significant differences between wild type and Nucb2 -/- mice in
peripheral glucose uptake (42.6 ± 2.6 and 46.6 ± 3.9 respectively, p=0.4) as well as no effects on
endogenous hepatic glucose production (EGP) in either the basal (15.0 ± 1.3 and 14.9 ± 0.9
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respectively, p=0.96) or the clamped state (1.5 ± 1.8 and 0.5 ± 1.0 respectively, p=0.62) (Figure
2.13). The sharp decrease in EGP through the clamp study shows high insulin sensitivity in the
liver in both mouse models.
There was also no dysfunction in pancreatic insulin secretion. Wild type and Nucb2 -/mice showed no difference in insulin production in both basal (5.2 ± 0.6 and 4.4 ± 1.7 respectively,
p=0.4) and clamped states (34.6 ± 1.9 and 35.6 ± 2.2 respectively, p=0.7). In line with these data,
adipocyte function did not appear to be affected by Nucb2-/- in chow-feeding, as reflected by no
difference in levels of insulin-stimulated plasma free fatty acids between wild type and Nucb2 /- mice (basal FFA: 1.06 ± 0.06 mEq/l and 1.11 ± 0.12, respectively, p=0.8), and clamped FFA: 0.34
± 0.06 and 0.38 ± 0.09, respectively, p=0.7). This result is reflected by a 66% insulin-stimulated
suppression of plasma fatty acids (Figure 2.14).
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Figure 2.13: Nucb2 does not affect whole body glucose homeostasis in lean chow fed mice
(A) Time-course of plasma glucose levels (B) Glucose Infusion Rate (C) Basal and Clamped plasma glucose levels (D)
End-point glucose infusion rate (E) Systemic glucose uptake during the steady-state period (final 40 min) of the clamp
(F) and Basal and insulin-stimulated clamped hepatic endogenous glucose production. Male 14 week old chow fed
mice and data are represented as mean ± SEM (wild type, n=8 and Nucb2 -/-, n=7)
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Figure 2.14: Nucb2 does not affect plasma insulin or plasma fatty acids
(A) Basal and clamped plasma insulin levels (B) Basal and insulin-stimulated clamped plasma free fatty acid levels (C)
NEFA (Non-esterified Fatty Acids) Plasma fatty acid suppression. Data are represented as mean ± SEM (wild type,
n=8 and Nucb2 -/-, n=7)

These data suggest that Nucb2 is not required for insulin signaling and overall glucose
homeostasis under normal, metabolically healthy chow fed conditions, as both Nucb2-/- mice
and wild type mice required a similar amount of glucose infusion to maintain euglycemia.
Moreover, there are no differences in plasma insulin, or plasma fatty acids between wild type
and Nucb2-/- mice.
Nucb2 is necessary for proper insulin signaling and regulation of glucose homeostasis in
high fat challenged mice
To determine if Nucb2 is important in the regulation of whole-body insulin action during
obesity-induced insulin resistance (HFD), we next performed hyperinsulinemic-euglycemic
clamps on WT and Nucb2-/- mice that were fed a 60% Kcal high fat diet for 12 weeks. Basal
characteristics (body weight and body fat mass) were not different between wild type and Nucb2
-/- mice (body weight: 27.02 ± 0.6 g and 28.51 ± 063 g, respectively, p=0.1 and body fat: 4.81 ±
0.36 g and 5.7 ± 0.5 g, respectively p=0.2) (Figure 2.15).
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In contrast to the results in the chow fed mice, Nucb2-/- mice fed a high fat diet displayed
a significant whole-body insulin resistance as reflected by an almost 50% decrease in the glucose
infusion rate (21.3 ± 2.1 and 11.0 ± 0.9, wild type and Nucb2 -/- respectively, p=0.002) required
to maintain euglycemia during the hyperinsulinemic-euglycemic clamp (Figure 2.16B).
There were no statistically significant differences between wild type and Nucb2 -/- mice
in whole-body glucose uptake (29.25 ± 2.24 and 24.8 ± 2.3 respectively, p=0.2) despite a trend
towards lower values in the knock out mice (Figure 2.16E). On the other hand, there was a
significant increase in EGP in the Nucb2 -/- clamped mice (wild type and Nucb2 -/-: 7.96 ± 1.75
and 13.79 ± 1.71 respectively p=0.04) but not in the basal state (wild type and Nucb2 -/-: 11.29 ±
0.88 and 10.97 ± 1.11 respectively p=0.8) (Figure 2.16F). This clearly suggests a state of liver
insulin resistance in which the liver is unable to shut down glucose production (primarily through
glycogenolysis and gluconeogenesis) in the face of increased in insulin levels.
We did not observe any effects of Nucb2 knockout on pancreatic insulin secretion. Wild
type and Nucb2 -/- mice showed no difference in insulin production in both basal (12.41 ± 1.47
and 14.19 ± 1.4 respectively, p=0.4) and clamped states (76.65 ± 6.3 and 75.23 ± 3.5 respectively,
p=0.9) (Figure 2.17). Remarkably, however, there seemed to be adipocyte dysfunction in Nucb2
-/- mice on a high fat diet, as reflected by a significant increase in insulin-stimulated plasma free
fatty acids in the Nucb2 -/- mice compared to wild type mice (basal FFA: 0.83 ± 0.06 mEq/l and
0.69 ± 0.09, respectively, p=0.2), and clamped FFA: 0.4 ± 0.03 and 0.63 ± 0.04, respectively,
p=0.0003) (Figure 2.17). This resulted in a 57% FFA suppression in wild type mice, and only a 2%
suppression in the Nucb2 -/- mice under clamped conditions. This suggests adipose tissue insulin
resistance, in which the adipose tissue does not shut down triglyceride lipolysis and continues to
release nonesterified fatty acids even though there is glucose available as energy in the clamped
state.
B

A

Figure 2.15: Nucb2 has no effect on body weight and body composition in HFD fed mice
(A) Body weight in grams and (B) fat mass in grams. All data are represented as mean ± SEM (12 week old, male wild
type, n=11 and Nucb2 -/-, n=8)
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Figure 2.16: Nucb2 ablation causes systemic and hepatic insulin-resistance in HFD fed mice
(A) Time-course of plasma glucose levels (B) Glucose Infusion Rate (C) Basal and Clamped plasma glucose levels (D)
End-point glucose infusion rate (E) Systemic glucose uptake during the steady-state period (final 40 min) of the clamp
(F) and Basal and insulin-stimulated clamped endogenous glucose output. Data are represented as mean ± SEM (wild
type, n=11 and Nucb2 -/-, n=8)
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Overall, these data illustrate that ablation of Nucb2 negatively impacts normal glucose
disposal and normal insulin signaling in animals fed a high fat diet. This is clearly seen by the
ability of wild type mice to clear infused glucose at a much higher rate than the Nucb2 -/- mice.
Moreover, the ablation of Nucb2 significantly alters liver insulin sensitivity, as seen by the
knockout animals’ inability to reduce hepatic glucose production under insulin-stimulated
clamped conditions.
A
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Figure 2.17: Nucb2 ablation has no effect on insulin secretion but leads to adipocyte insulin
resistance
(A) Basal and clamped plasma insulin levels (B) Basal and insulin-stimulated clamped plasma free fatty acid levels (C)
Plasma fatty acid suppression. Data are represented as mean ± SEM (wild type, n=11 and Nucb2 -/-, n=8)
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These data further show that ablation of Nucb2 does not affect insulin secretion. Nucb2 /- mice do, however, show significant adipose tissue insulin resistance as evidenced by their
inability to suppress the lipolysis and ultimate secretion of fatty acids into plasma throughout the
course of the clamp.

2.4 Discussion
The major findings of these studies are: 1) While Nucb2 expression is not regulated by
diet or age in the hypothalamus, liver or visceral adipose tissue, it is significantly up-regulated in
isolated macrophages and T cells derived from the adipose tissue of HFD-fed mice; 2) Nucb2 does
not modulate food intake, body weight and body composition; 3) Nucb2 is not required for
normal glucose homeostasis, insulin secretion and insulin sensitivity in lean, chow fed mice. 4)
Nucb2 is, however, required for insulin sensitivity and glucose homeostasis during hypercaloric,
high fat diet feeding as loss of Nucb2 causes severe insulin-resistance in obesity.
Previous studies have shown nesfatin-1 to be an anorexigenic molecule [14, 152]. Our
data, however show that removal of the Nucb2 gene, and thus endogenous, physiological levels
of Nucb2, does not affect food intake, as assessed by both direct measurement of food consumed
as well as mRNA expression of AgRP. Together, these findings indicate that Nucb2 is not an
important regulator of feeding and that it does not interact with the neuropeptides NPY and
AgRP, themselves accepted regulators of food intake [153-156]. It is plausible that previous
studies demonstrating anorexigenic actions implicative of Nucb2 might see a pharmacological
effect of supraphysiological doses of intracerebroventricularly injected nesfatin-1 [14, 23, 129,
140]. It is important to note, however, that previous studies using commercially available
antibodies are unable to specifically detect nesfatin-1. Furthermore, nesfatin-1 alone may affect
food intake, while Nucb2 may have pleiotropic effects that are compensated or controlled by
nesfatin-2 or nesfatin-3, whose functions remain unknown. To further delineate the importance
of these three individual peptides, it would be necessary to inhibit only one or use recombinant
proteins to reintroduce each peptide alone and in combinations with one another. In support of
our demonstrations of a lack of effect of Nucb2 on ingestive behavior, however, is a recent study
showing that Nucb2/Nesfatin-1 does not change daily food intake or modify mRNA expression
levels of orexigenic (NPY, AgRP) or anorexigenic (POMC) proteins [157]. Interestingly, much like
our genetic approach, this study used a genetic overexpression model of Nucb2, whereas
previous studies linking Nucb2/nesfatin-1 to regulation of food intake were all pharmacologic.
The magnitude of reduced glucose infusion during a hyperinsulinemic-euglycemic clamp
in Nucb2 deficient mice on a high fat diet is drastic (50%), clearly indicating a role of Nucb2 in the
regulation pathways of insulin sensitivity. Furthermore, the data show that Nucb2 is important
for insulin sensitivity especially in adipose tissue by its inability to suppress lipolysis and
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circulating free fatty acids and in liver which becomes unable to shutdown endogenous glucose
production during the insulin-stimulated clamp. Together, these data indicate that Nucb2 is
necessary for appropriate insulin signaling and glucose uptake in metabolic tissues in dietinduced obesity and its related insulin impaired insulin resistance.
Consistent with initial cloning of Nucb2 in B-lymphocyte cell lines, Nucb2 is highly
expressed in different leukocyte subpopulations such as macrophages, T-lymphocytes and
plasmacytoid dentritic cells. Furthermore, Nucb2 expression levels in adipose derived
macrophage and T cells are positively regulated by a high fat diet. In line with our observations,
other studies have shown that Nucb2 and nesfatin-1 levels are significantly higher in different
depots in high-fat fed mice and reduced under food deprivation [134]. This group further showed
that stimulation of subcutaneous adipose tissue explants with cytokines TNF-α and IL-6, insulin
and dexamethasone significantly increases intracellular nesfatin-1 levels [134]. Due to the high
expression of Nucb2 in immune cells and an increase in leukocyte Nucb2 expression following
high fat feeding, we hypothesize that Nucb2 is important in the activation and/or regulation of
immune cells.
Our results confirmed the importance of Nucb2 in regulating local metabolism
(occurrence of local insulin resistance) thus probably protecting the tissue from more deleterious
damage (cell death for example). It also identifies a dissociation between the physiological
regulation of energy metabolism (energy intake and energy expenditure) and the level of insulin
resistance. Such observation may remind us that all the anabolic periods of life such as puberty
and pregnancy are first characterized by a state of insulin resistance.
In conclusion, ablation of Nucb2 failed to influence body weight, body composition or
food intake under chow or high fat diet conditions, thus suggesting that Nucb2 has no role in the
physiological regulation of food intake or overall energy metabolism. On the other hand, Nucb2
appears to be an important insulin sensitizer during obesity-induced insulin resistant states, and
is required for normal glucose metabolism and glucose homeostasis. This is evident by the
derangement in glucose homeostasis in the Nucb2 -/- mice. Weisberg et al. (2003) showed that
leukocytosis in adipose tissue is directly correlated with adiposity [158] and that increased
expression of immune cell proinflammatory cytokines increases insulin resistance [92]. Since
Nucb2 expression levels are abundant in immune cells and are increased in immune cells during
high fat feeding, it is thus important to determine if Nucb2 plays a regulatory role in immune cell
activation or proliferation, and if this high fat induced expression of Nucb2 leads to regulation of
cytokine production.
The current findings, in conjunction with previous literature, leads to the hypothesis that
increases in Nucb2 expression in macrophages and T cells under conditions of high fat feeding
serve as a regulatory mechanism to dampen inflammation. Thus, under conditions of high fat
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feeding and in the absence of Nucb2, the knockout mice should be unable to adapt to obesityinduced immune cell inflammatory cytokine production, ultimately leading to insulin resistance.
While our results show that Nucb2 is clearly important in obesity induced metabolic
dysregulation of insulin signaling and glucose metabolism, we have yet to determine if Nucb2 is
affecting the insulin receptor directly or other potential glucose transport proteins involved in
glucose uptake into tissues.
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Figure 2.18: Major findings and conclusions from Chapter 2
Ablation of Nucb2 renders mice to become extremely insulin resistant during high fat diet induced obesity. From our clamp data, it is evident that the Nucb2-/mice have insulin resistance in adipocytes and hepatocytes. Mice lacking Nucb2 are unable to shut down hepatic glucose production or lipolysis under insulin
induced clamped conditions.
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Chapter 3: Effects of Nucleobindin-2 on Myeloid Cells and Lymphocytes and
Sterile Obesity-induced Inflammation
3.1 Introduction
With excess energy stores as lipids in adipocytes, obesity-related low-grade systemic
inflammation contributes to the pathogenesis of at least seven out of ten of the leading causes
of mortality. These include type 2 diabetes, heart disease, some forms of cancer, chronic lower
respiratory disease, stroke, Alzheimer’s disease, and kidney disease [7-13]. In a classical
immunologic response, inflammation is characterized as an acute response to tissue damage or
pathogen associated molecular patterns (PAMPs). These immunologic responses are necessary
for host defense against infections and tissue remodeling in response to tissue injury. However,
obesity-related sterile inflammation is not associated with overt infections and is a result of the
activation of an immune response to self (increases in FFA’s seen in obese) or typically innocuous
stimuli (extracellular ATP or cholesterol crystals) in absence of infections. In obesity and aging,
this sterile inflammation is hypothesized to be a fundamental cause for disruption of normal
metabolic function which over time leads to degenerative diseases.
Over the years, more appreciation has been given to the link between inflammation and
the pathogenesis of type 2 diabetes. Together with the discovery of the importance of adipose
tissue leukocytosis, new findings are helping to explain how obesity increases the risk for
developing insulin resistance, some facets of the metabolic syndrome and eventually diabetes.
In 2003, Ferrante et al. showed that obesity is positively correlated with macrophage influx in
adipose tissue which alters metabolic and endocrine function [158]. They showed that adipose
tissue macrophages were responsible for almost all adipose tissue TNA-α expression and
significant amounts of iNOS and IL-6 expression.
Hotamisligil et al. (1993) initially demonstrated that the proinflammatory cytokine TNF-α
is able to directly induce insulin resistance [6]. The concept that adipose tissue was a site for the
production of cytokines and hormones extended beyond TNF-α to include IL-1β, IL-6, leptin,
monocyte chemoattractant protein-1, PAI-1, serum amyloid A and others [17, 159-161]. While
some of these factors are true adipokines, many of these molecules are expressed at high levels
in activated macrophages or other immune cell subtypes. Regardless, they undoubtedly
participate in the induction and maintenance of the subacute inflammatory state associated with
obesity and type 2 diabetes.
Ever evolving is the concept that insulin resistance and diabetes have immunological
components. Moreover, improving knowledge of how inflammation modulates metabolism may
provide new opportunities for using anti-inflammatory strategies as a therapy for the different
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impairments occurring with the cardiometabolic syndrome progressively occurring with excess
adiposity.
The studies described in Chapter 2 showed Nucb2 expression was increased in adipose
tissue macrophages and T cells from mice fed a HFD. We were thus interested in further exploring
what role Nucb2 might be playing in these immune cell subsets. To further delve into the
mechanisms underlying the insulin resistance phenotype seen our my Nucb2-/- mouse model,
we set out to test if Nucb2 is important in immune cell activation and/or chronic, low grade
systemic inflammation that commonly accompanies gains in adipose tissue in obesity. To do this,
we studied the changes in immune cell activation via in-vitro cultures of femur bone marrow
derived macrophages and in vivo gene expression models.

3.2 Materials and Methods
Cell isolation, flow cytometry and Fluorescence-Activated Cell Sorting (FACS)
Cells were isolated from adipose tissues using FACS technique. Antibodies used were CD3,
F4/80, and B220 (eBioscience Affymetrix). Cells were acquired on a BD FACSCalibur, and data
were analyzed in FlowJo (Treestar Inc., Ashland, OR, USA). To identify naïve and effector/memory
T cells, splenocytes and Stromal Vascular Fraction (SVF) were incubated with fluorescently
labeled PerCP-conjugated anti-CD4, APC-conjugated anti-CD8, PE-conjugated anti-CD62L, and
FITC-conjugated anti-CD44 antibodies. SVF was also stained with anti-F4/80, CD11b, CD206
(eBiosciences, San Diego, CA, USA and Biolegend, San Diego, CA, USA) to assess macrophage and
granulocyte populations. Data were acquired on a BD LSR II and analyzed using FlowJo.
Leukocyte quantification in adipose tissue
Leukocytes were quantified in inguinal and epididymal fat pads using flow cytometry
analysis as previously described by our laboratory (Quantification of Adipose Tissue Leukocytosis
in Obesity) [147]. Cells were labeled using antibodies described below, and cells were run on a
FACSCalibur (BD Biosciences, San Jose, CA, USA). Macrophage subsets were identified using
F4/80, CD206 and CD11c antibodies (eBiosciences, San Diego, CA, USA and Biolegend, San Diego,
CA, USA). T cell subpopulations were identified by CD3, CD4 and CD8 antibodies, while B cell
populations were identified by B220 antibodies for B220, IgM and CD19 (eBiosciences). FACS data
were analyzed by post-collection compensation using FlowJo software (Treestar Inc., Ashland,
OR).
Cell cultures
[All steps were performed using sterile technique in a laminar flow hood] Mouse femurs
were collected in RPMI (22400105; Life Technologies) + 10% FBS (R10; Omega Scientific) + 1%
Antibiotic-antimycotic (15240062; Gibco Thermofisher). Both ends of the femur were then cut
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and the femur was flushed with R10. The bone marrow was centrifuged at 450 g for 5 min, the
supernatant was decanted and red blood cells were lysed using ACK lysis buffer (118-156-101;
Quality Biological). After neutralization with R10, bone marrow cells were centrifuged,
suspended in 10 ml of R10 and placed into a six-well plate. Non-adherent cells were collected the
following morning. The non-adherent cells were resuspended at 4 × 106 cells per ml in medium
consisting of 10 ml supernatant of non-adherent cells, 7.2 ml L929 conditioned medium, 6.8 ml
R10 and MCSF (10 ng/ml; 416-ML; R&D Systems). After 4 days, an additional 2 ml of fresh medium
was added. Non-adherent cells were collected on day 7, separated by density gradient separation
using Fico/Lite (I40650; Atlanta Biologicals) and mononuclear cells were collected. Cells were
rinsed twice with Dulbecco's PBS + 2% FBS, and resuspended at 1 × 106 cells per ml. Cells were
treated with ultrapure LPS (L6529-1mg, Sigma-Aldrich, St Louis, MO, USA) alone for 4 hrs or in
combination with 5 mM ATP (1A7699-1G; Sigma-Aldrich, St Louis, MO, USA) for 1 hr, 4 ng/uL IFNγ, 1ng/ml IL-4, 200ug/ml silica for 5 hrs. During the course of this work, some of the macrophages
were pre-treated for 12 hrs with 10 mM, 20 mM or 40 mM Bay-11-7085 compound (B5681;
Sigma-Aldrich, St Louis, MO, USA), which irreversibly inhibits the TNFα-inducible phosphorylation
of IκB-α (IC50 = 10 µM) without affecting the constitutive IκB-α phosphorylation at indicated
concentrations and time. The cell supernatants and cell lysates were collected after treatment
and analyzed for different proinflammatory markers either by western blot or quantitative PCR.
Western Blotting
Bone marrow derived macrophage cell lysates were prepared using RIPA buffer and
immediately snap frozen in liquid nitrogen. Samples were vortexed every 10 min for 1 hr. Samples
were centrifuged at 14,000 g for 15 min, the supernatant was collected and the protein
concentration was determined using the DC Protein Assay (Bio-RAD). Antibodies to IL-1β (1:500,
GTX74034; Genetex), NFκB p65 (1:1,000 8242s, Cell Signalling), phosphorylated-NFκB p65
(1:1000 3033S, Cell Signaling), and β-actin (1:1,000 4967L; Cell Signaling) were used at the
dilutions specified by the manufacturer. The immune complexes were visualized by incubation
with horseradish peroxidase-conjugated anti-rat (PI31470; Pierce) or anti-rabbit secondary
antibody (PI31460, Pierce). Immuno-reactive bands were visualized by enhanced
chemiluminescence (PI32209; Pierce). Densitometry analysis was performed using the ImageJ
Gel Analysis tool, where gel background was also removed individually for each band.
Quantitative PCR
RNA from tissue and cells were isolated using an RNeasy Plus mini and micro kit (Qiagen;
74106 and 74034) according to the manufacturer's instructions. DNA digestion was performed
on the colums using RNase-Free DNase according to manufacturer's instructions (79254; Qiagen).
Following RNA purification, these samples were then used for iScript cDNA synthesis using a
reverse transcriptase PCR kit (BIO-RAD; Hercules, CA, USA). Quantitative PCR was performed with
the LightCycler 480 II (Roche Applied Science; Indianapolis, IN, USA) and Power SYBR Green
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detection reagent (Applied Biosystems by Thermo Fischer Scientific; Woolston Warrington, UK).
Primer sequences for transcripts encoding proteins involved in lipid and glucose metabolism
were designed with Primer Express Software. For Nucb2, we used the forward primer sequence
5'-AAAACCTTGGCCTGTCTGAA-3'
and
the
reverse
primer
sequence
5'CATCGATAGGAACAGCTTCCA-3'. For CCL4, we used the forward primer sequence 5’GAAACAGCAGGAAGTGGGAG-3’
and
the
reverse
primer
sequence
5’CATGAAGCTCTGCGTGTCTG-3’. For IL-1β, we used the forward primer sequence 5’GGTCAAAGGTTTGGAAGCAG-3’ and the reverse primer sequence 5’-TGTGAAATGCCACCTTTTGA3’. For IL-6, we used the forward primer sequence 5’-ACCAGAGGAAATTTTCAATAGGC-3’ and the
reverse primer sequence 5’-TGATGCACTTGCAGAAAACA-3’. For TNF-α, we used the forward
primer sequence 5’-AGGGTCTGGGCCATAGAACT-3’ and the reverse primer sequence 5’CCACCACGCTCTTCTGTCTAC-3’. For MIP-1α, we used the forward primer sequence 5’ACCATGACACTCTGCAACCA-3’ and the reverse primer sequence 5’-GTGGAATCTTCCGGCTGTAG3’.
In all qRT-PCR experiments, 25 ng cDNA was used. Fold induction of gene expression with
Nucb2 was analyzed with the ΔΔCt method (also known as the comparative Ct method) as
determined by the following equation: ΔΔCt = ΔCt treatment (WT NFκB inhibited - ΔCt control
(WT control)). Here, the ΔCt is the Ct value for the sample treatment normalized to the
endogenous housekeeping GAPDH transcript.
Whole Transcriptome Sequencing (mRNA-seq)
Optical density values of extracted RNA were measured using NanoDrop (Thermo
Scientific) to confirm an A260:A280 ratio above 1.9. RNA integrity number (RIN) was measured
using BioAnalyzer (Agilent) RNA 6000 Pico Kit to confirm RIN above 7.
Samples were then run by the Yale Center for Genome Analysis using Clontech ultra lowinput Library Prep Kit V2 (#634899, Clontech Laboratories, Inc. Mountain View, CA, USA).
Samples were sequenced using single-end 1x75 on the Illumina HiSeq2500 (Illumina
Biotechnology, San Diego, CA, USA). Read counts were normalized using DESeq2 (R-package) in
collaboration with Life & Medical Sciences Institute at the University of Bonn. To avoid spurious
fold changes during differential expression analysis, all normalized counts were set to a value of
at least 1.
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3.3 Results
Nucb2 is not required for immune cell chemotaxis or adipose tissue leukocytosis
Previous studies have shown that mice fed a HFD recruit innate and adaptive immune
cells in their epididymal white adipose tissue as they gain weight [22, 103, 104, 158]. Using
fluorescence-activated cell sorting (FACS), we were able to quantitatively assess the kinetics of
the immune cell subsets that infiltrate the different adipose tissue depots in mice fed different
diets.
In mice fed a HFD, there was no difference in the immune cell subset frequencies within
the adipose tissues. In inguinal adipose tissue, the myeloid lineage cells represented 11.4 ± 1.5%
and 12.3 ± 0.4% in wild type and Nucb2 -/- mice, respectively (p=0.5), whereas macrophage
populations were similarly unchanged between wild type and Nucb2-/- mice (16.7 ± 1.5% and
14.6 ± 0.9%, respectively, p=0.2). There were also no differences in myeloid cells (WT and KO:
11.8 ± 1.6% and 11.5 ± 0.7%, respectively, p=0.9) or macrophages (22.8 ± 4.4% and 23.1 ± 1.6%,
respectively, p=0.1) frequencies in visceral mesenteric adipose tissue. Similarly, no differences
were detected in visceral perirenal adipose tissue myeloid (WT and KO: 10.4 ± 0.6% and 10.7 ±
1.3%, respectively, p=0.8) and macrophages (WT and KO: 16.6 ± 2.7% and 19.8 ± 1.3%,
respectively, p=0.3) (Figure 3.1).
In addition to no differences in myeloid lineage cells in different adipose tissue depots,
there was also no difference in frequencies of lymphocyte populations. In inguinal adipose tissue,
there were no differences in lymphocyte frequencies between wild type and Nucb2-/- mice (44.3
± 3.2% and 48.2 ± 3.7%, respectively, p=0.5), in CD4+ helper T cells (12.1 ± 1.9% and 10.6 ± 1.3%,
respectively, p=0.5) and in CD8+ cytotoxic T cells (12.3 ± 1.5% and 13.7 ± 1.1%, respectively,
p=0.5). T cells were further divided into different subsets of CD4+ and CD8+ cells. To further
characterize the subset of T cells in the inguinal adipose tissue, we studied potential differences
in the prevalence of naïve and effector/memory cells. To identify these cells, we sorted the cells
for cell surface glycoproteins such as CD44 and cell adhesion molecule CD62L (L-selectin). Even
with these extra characterizations, we saw no differences between wild type mice and Nucb2-/mice. CD4 naïve cell frequencies were similar between wild type and Nucb2-/- mice (2.3 ± 0.4%
and 3.3 ± 1.0%, respectively, p=0.5), as were CD4 effector/memory cells (37.0 ± 2.8% and 36.3 ±
1.7%, respectively, p=0.8). CD8 naïve cell frequencies were 1.9 ± 0.2% and 2.4 ± 0.6% for wild
type and Nucb2-/- respectively (p=0.5), and CD8 effector/memory cell frequencies were 46.3 ±
4.11% and 42.8 ± 2.2% in wild type and Nucb2-/- respectively, p=0.4 (Figure 3.2). These data show
that there are no differences in adipose tissue leukocytosis between wild type and Nucb2-/- mice,
and that Nucb2 is not required for leukocyte chemotaxis.
In visceral mesenteric adipose tissue, frequencies of lymphocytes (50.8 ± 9.27% and 61.3
± 3.23%, respectively, p=0.2), CD4+ helper T cells (13.4 ± 2.0% and 15.2 ± 1.5%, respectively,
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p=0.5) and CD8+ cytotoxic T cells (8.7 ± 2.8% and 11.2 ± 1.5%, respectively, p=0.4) were all similar
between wild type and Nucb2-/- mice. Similarly to inguinal adipose tissue, there were no
differences between naïve and effector/memory cells in the mesenteric depot. CD4 naïve cell
frequencies were 3.8% ± 1.4% and 3.6 ± 0.6% for wild type and Nucb2-/- animals, respectively
(p=0.9). Interestingly, CD4 effector/memory cell frequencies were 47.1 ± 5.5% and 57.4 ± 1.9%
with increases seen in Nucb2-/- mice (p=0.05). CD8 naïve cell frequencies were 3.2 ± 0.9% and
2.9 ± 0.5% for wild type and Nucb2-/- respectively (p=0.8) and CD8 effector/memory cell
frequencies were 45.0 ± 4.8% and 48.8 ± 1.8%, wild type and Nucb2-/- respectively, p=0.4 (Figure
3.3).
In visceral perirenal adipose tissue, there were also no differences in lymphocyte
frequencies between wild type and Nucb2-/- mice (25.8 ± 6.5% and 19.2 ± 4.1%, respectively,
p=0.4), CD4+ helper T cells (10.4 ± 0.9% and 7.7 ± 1.5%, respectively, p=0.2) and CD8+ cytotoxic
T cells (13.1 ± 2.7% and 16.9 ± 2.1%, respectively, p=0.3). As in other adipose depots, there were
no differences between naïve and effector/memory cells in the perirenal depot. CD4 naïve cell
frequencies were 5.9% ± 1.9% and 3.8 ± 0.9% for wild type and Nucb2-/- mice, respectively
(p=0.3), and CD4 effector/memory cell frequencies were 37.4 ± 2.7% and 41.0 ± 4.4%, for wild
type and Nucb2-/- animals, respectively, p=0.6. CD8 naïve cell frequencies were 1.5 ± 0.7% and
1.2 ± 0.3% for wild type and Nucb2-/- mice, respectively (p=0.5), and CD8 effector/memory cell
frequencies were 47.3 ± 4.7% and 48.8 ± 2.2%, wild type and Nucb2-/- animals, respectively,
p=0.7(Figure 3.4).
Overall, there were no differences in immune cell leukocytosis in the different adipose
tissues examined. There were also no differences in frequencies of both myeloid and lymphoid
lineage cells in the adipose tissue depots harvested from mice fed a high fat diet. This is
imperative to conclude that Nucb2 does not have an effect on chemotaxis of immune cells to
tissues. In conclusion, the migration and differentiation of immune cell subsets were not affected
by ablation of the Nucb2 gene.
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Figure 3.1: Nucb2 ablation does not impact the number of macrophages in adipose tissue
Representative flow cytometry dot plots of SVF from subcutaneous inguinal adipose tissue, visceral mesenteric
adipose tissue and visceral perirenal adipose tissue with corresponding quantitation. Macrophage populations in (A)
Inguinal adipose tissue gating strategy and macrophage quantifications, (B) Visceral mesenteric adipose tissue gating
strategy and macrophage quantifications and (C) Visceral perirenal adipose tissue gating strategy and macrophage
quantifications. All data are represented as mean ± SEM (mice are 8 month old, male high fat diet fed wild type, n=5
and Nucb2 -/-, n=8)
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Figure 3.2: Nucb2 ablation does not affect inguinal adipose tissue lymphocyte nor T cell subset
frequency
Lymphoid populations in inguinal adipose tissue. (A) Flow gating strategy for the lymphoid T cell subset analysis (B)
Lymphoid cell quantification (C) CD4 and CD8 positive T cell subset quantification (D) CD4+ naïve and
effector/memory quantifications and (E) CD8+ naïve and effector/memory quantifications. All data are represented
as mean ± SEM (mice are 8 month old, male high fat diet fed wild type, n=5 and Nucb2 -/-, n=8)
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Figure 3.3: Nucb2 ablation does not affect visceral mesenteric adipose tissue lymphocyte nor T
cell subset frequency
Lymphoid populations in mesenteric adipose tissue. (A) Flow gating strategy for the lymphoid T cell subset analysis
(B) Lymphoid cell quantification (C) CD4 and CD8 positive T cell subset quantification (D) CD4+ naïve and
effector/memory quantifications and (E) CD8+ naïve and effector/memory quantifications. All data are represented
as mean ± SEM (mice are 8 month old, male high fat diet fed wild type, n=5 and Nucb2 -/-, n=8)
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Figure 3.4: Nucb2 ablation does not affect visceral perirenal adipose tissue lymphocyte nor T cell
subset frequency
Lymphoid populations in visceral perirenal adipose tissue. (A) Flow gating strategy for the lymphoid T cell subset
analysis (B) Lymphoid cell quantification (C) CD4 and CD8 positive T cell subset quantification (D) CD4+ naïve and
effector/memory quantifications and (E) CD8+ naïve and effector/memory quantifications. All data are represented
as mean ± SEM (mice are 8 month old, male high fat diet fed wild type, n=5 and Nucb2 -/-, n=8)
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Nucb2 is important for regulation of proinflammatory cytokine production in classically
activated M1-like macrophages
Since Nucb2 is highly expressed in leukocytes, we next determined if there were
differences in macrophage sub-population activation state and/or polarization. Classically
activated (M1) macrophages are predominantly proinflammatory, are dependent on TLRs, and
have the role of effector cells in Th1 cellular immune responses. The alternatively activated (M2)
macrophages are involved in immunosuppression and tissue repair and are considered more
anti-inflammatory. The outer membrane of Gram-negative bacteria, endotoxin
lipopolysaccharide (LPS) and the Th1 cytokine IFN-γ polarize macrophages towards the M1
phenotype, inducing the macrophages to produce large amounts of proinflammatory cytokines.
Using an in vitro bone marrow derived macrophage (BMDM) model, we tested whether Nucb2 is
required for normal macrophage function in chosen macrophage subsets, and determined if
Nucb2 partially regulates inflammatory cytokine production.
There were no differences in proinflammatory cytokine production between wild type
and Nucb2 -/- mice in basal, unpolarized M0 macrophages. As expected, however, there was a
significant increase in proinflammatory cytokine production in M0 vs. M1 polarized macrophages
in both wild type and Nucb2-/- mice. Intriguingly, Nucb2-/- “M1” polarized macrophages had
significant increases in relative fold change expression of TNF-α (WT and Nucb2-/-: 5.8 ± 0.3 and
9.7 ± 0.3, respectively, p=0.0001), IL-1β (WT and Nucb2-/-: 9.1 ± 1.5 and 23.9 ± 1.7, respectively,
p=0.0006), MIP-1α (WT and Nucb2-/-: 1.2 ± 0.1 and 2.4 ± 0.3, respectively, p=0.01) and CCL4 (WT
and Nucb2-/-: 1.4 ± 0.0 and 2.4 ± 0.3, respectively, p=0.007) (Figure 3.5). To validate our skewing
of macrophages, we measured classical markers of M1 macrophages (iNOS) and M2
macrophages (Arginase-1). Relative expression of iNOS was significantly increased in M1 skewed
macrophages, with even more elevated levels in Nucb2-/- macrophages when compared to WT
(WT and Nucb2-/-: 5.8 ± 0.3 and 9.7 ± 0.3, respectively, p=0.0001).
To confirm this increase in proinflammatory cytokine production, we conducted several
experiments on “M1” polarized macrophages to evaluate proinflammatory cytokine production.
The above outcomes were corroborated many times, showing Nucb2-/- “M1” polarized
macrophages have significant increases in cytokine production rates compared to wild type
controls. Fold change of the relative expression of TNF-α (WT and Nucb2-/-: 1.0 ± 0.0 and 1.9 ±
0.1, respectively, p=0.0003), IL-1β (WT and Nucb2-/-: 1.0 ± 0.1 and 1.7 ± 0.1, respectively,
p=0.0003), MIP-1α (WT and Nucb2-/-: 1.0 ± 0.04 and 2.0 ± 0.19, respectively, p=0.002), CCL4 (WT
and Nucb2-/-: 1.0 ± 0.0 and 1.8 ± 0.1, respectively) as well as iNOS (WT and Nucb2-/-: 1.0 ± 0.0
and 1.6 ± 0.1, respectively, p<0.0001) were all increased in Nucb2 deficient macrophages vs. wild
type macrophages. Nucb2 expression levels were verified as a control, and there was indeed no
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gene expression of Nucb2 in the knock out BMDMs (WT and Nucb2 -/-: 1.0 ± 0.03 and 0.00002 ±
0.0001, respectively, p<0.0001) (Figure 3.6).
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Figure 3.5: qRT-PCR to demonstrate Nucb2 ablation impacts macrophage polarization and
increases the expression of proinflammatory cytokines in M1-like BMDMs
Primary bone marrow derived macrophages (BMDMs) from wild type mice and Nucb2 -/- mice were treated with
media alone for unpolarized “M0” macrophages, 1 ug/mL LPS plus 4 ng/mL interferon gamma (IFNγ) to drive the
proinflammatory classically activated “M1” macrophages, or 1ng/ml IL-4 to drive anti-inflammatory alternatively
activated “M2” macrophages . (A) TNF-α relative gene expression levels (B) IL-1β relative gene expression levels (C)
MIP-1α relative gene expression levels and (D) CCL4 relative gene expression levels (E) inducible Nitric Oxide
Synthase (iNOS) relative gene expression levels and (F) Arginase-1 relative gene expression levels. All data are
represented as mean ± SEM (n=3/4 per group). *p< 0.05
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Figure 3.6: qRT-PCR to demonstrate Nucb2 ablation increases the expression of proinflammatory
cytokines in M1-like macrophages
Primary bone marrow derived macrophages (BMDM) from wild type mice and Nucb2 -/- mice were treated with
media and 1 ug/mL LPS plus 4 ng/mL interferon gamma (IFNγ) to drive the proinflammatory “M1" phenotype. (A)
TNF-α relative gene expression levels (B) IL-1β relative gene expression levels (C) MIP-1α relative gene expression
levels (D) CCL4 relative gene expression levels (E) iNOS and (F) Nucb2. All data are represented as mean ± SEM (n=4
per group). *p< 0.05 relative to wild type

Taken together, our data indicate that Nucb2 is required for regulating inflammatory
cytokine production. Absence of Nucb2 renders BMDM cells constitutively more skewed in a M1like classically activated macrophage state with significantly increased levels of proinflammatory
cytokines.
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Nucb2 regulates NFκB and IL-1β secretion in activated macrophages
IL-1β is sequestered as pro-IL-1β and requires post translational cleavage to become
active. Pro-IL-1β can be cleaved and activated by the NLRP3 inflammasomes. NLRP3 is an
important innate immune sensor that requires 2 different signals for activation and cleavage of
pro- IL-1β and pro-IL-18. NFκB is a protein complex that controls transcription of inflammasomes
NLRP3, as well as proinflammatory cytokine production and cell survival. In unstimulated cells,
NFκB dimers are sequestered in the cytoplasm by a family of inhibitors. However, when activated
by a cascade of enzymatic processes, active NFκB is translocated to the nucleus. LPS is a PAMP
that activates TLR4 which in turn activates NFκB and further the transcription of inflammasome.
Therefore, it is not surprising that NFκB is found to be chronically active in many inflammatory
diseases is signal 1 for inflammasome activation. Second signal is in response to structurally
diverse damage- DAMPs such as toxins, ATP, excess glucose, ceramides, amyloids, urate and
cholesterol crystals and is necessary for the activation and NLRP3 complex formation.
To determine the mechanistic pathway by which Nucb2 is working in the inflammatory
cascade, we studied IL-1β protein production in supernatant, as well as NFκB in cell lysates.
Ablation of Nucb2 significantly increased protein levels of both IL-1β and NFκB, as assessed by
western blotting. These results suggest that Nucb2 has suppressive activity on NFκB and possibly
on inflammasomes.

A

B

Figure 3.7: Nucb2 ablation increases NFκB activation and IL-1β secretion in response to NLRP3
ligands
Representative Western blot analysis of (A) IL-1β (active p17) in the supernatant and (B) NFκB (p65) in the cell lysates
of BMDMs primed with LPS for 4 h and stimulated with ATP for 1 h, Ceramide for 6 hrs or Silica for 5 hrs in wild type
or Nucb2-/- derived cells.

Overall, the above data show that ablation of Nucb2 constitutively increases protein levels
of NFκB and active phosphorylated NFκB. Also, Nucb2-/- increases the production and secretion
of activated proinflammatory IL-1β. These data indicate that Nucb2-/- BMDMs have increased
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secretion of IL-1β in response to different stimuli. Furthermore, BMDMs lacking Nucb2 exhibit
considerably more signal 1 as seen by increased NFκB and phosphorylated NFκB (Figure 3.7). To
further dissect mechanisms of Nucb2, It would be necessary to test if there is increased amounts
of NLRP3 or other inflammasomes.
Nucb2 regulates proinflammatory cytokine expression in macrophages via NFκB activation
M1 macrophage activation is dependent on TLRs and on activation of nuclear factor kappa
B (NFκB) and c-Jun N-terminal kinase 1 (JNK1), leading to production of inflammatory cytokines,
such as TNF-α and IL-1β. These cytokines in turn activate iNOS, resulting in increased production
of reactive oxygen species such as nitric oxide (NO). To determine if the increased production of
inflammatory cytokines seen in Nucb2-/- mice is dependent on the canonical NFκB pathway, we
used an inhibitor of NFκB. The Bay-11-7085 NFκB inhibitor irreversibly impedes TNFα-inducible
phosphorylation of IκB-α (IC50 = 10 µM) without affecting constitutive IκB-α phosphorylation.
This in turn prevents the translocation of RelA/p50 to the nucleus and activation of the
transcription of proinflammatory cytokines.
This experiment (Figure 3.8) indicated that the effects seen in Nucb2 -/- BMDMs are
mediated by the NFκB pathway. When NFκB was blocked, the increases in proinflammatory
cytokine production were all attenuated. Corroborating with our previous BMDM studies, Nucb2/- mice without NFκB inhibitor have significantly augmented proinflammatory cytokine
production compared to wild type controls. TNF-α relative expression levels were 2.27 ± 0.31 fold
higher (p=0.002), IL-1β relative expression levels 3.6 ± 0.22 fold higher (p<0.0001), MIP-1α
relative expression levels 2.69 ± 0.38 fold higher (p=0.0009) and CCL4 relative expression levels
2.47 ± 0.24 fold higher (p=0.0002) in Nucb2 -/- compared to wild type control mice. Remarkably,
these increased levels of proinflammatory cytokines were almost completely attenuated when
the NFκB pathway was inhibited by the Bay-11-7085 NFκB compound. When NFκB was inhibited,
TNF-α relative expression levels were attenuated from 2.27 ± 0.31 to 1.21 ± 0.2 fold (p=0.02), IL1β relative expression levels from 3.6 ± 0.22 to 1.6 ± 0.19 fold (p=0.0001), MIP-1α relative
expression levels from 2.69 ± 0.38 to 1.27 ± 0.14 fold (p=0.008) and CCL4 relative expression
levels from 2.47 ± 0.24 to 1.47 ± 0.1 fold (p=0.006) higher compared to wild type control mice
(Figure 3.8). These data demonstrate that Nucb2 regulates inflammation through the NFκB
pathway.
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Figure 3.8: Regulation of pro-inflammatory cytokines by Nucb2 is mediated by NFκB
Primary bone marrow derived macrophages (BMDMs) from wild type mice and Nucb2 -/- mice were treated with
media and 1 ug/mL LPS plus 4 ng/mL interferon gamma (IFNγ) to drive the proinflammatory “M1" phenotype. Some
macrophages were pretreated with Bay-11-7085 NFκB inhibitor. (A) TNF-α relative gene expression levels (B) IL-1β
relative gene expression levels (C) MIP-1α relative gene expression levels and (D) CCL4 relative gene expression
levels. All data are represented as mean ± SEM (n=6 per group). *p< 0.05 relative to wild type

Visceral adipose tissue macrophages from Nucb2-/- mice have increased proinflammatory
cytokine production
As a model system to study the function of the highly diversified and complex cell type
that is the macrophage, BMDMs are a good source for gene function studies and provide an
abundant source of cells. However, it is important to note that differences in culturing technique
can lead to phenotypic differences and functional disparities, including alterations in cell surface
maturation markers and in the ability to secrete cytokines and phagocytose foreign materials
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[162]. To eliminate this potential technical bias and examine whether the observed phenotypic
differences and identified mechanism were physiologically relevant, we set out to determine if
the above results were in fact replicable in an in vivo model. To do so, we used antibody against
macrophage specific F4/80 cell surface glycoprotein and FACS sorted macrophages directly from
the visceral adipose tissue of mice (Nucb2 -/- and WT control).
The increased proinflammatory state seen in BMDMs was also seen in isolated primary
F4/80+, adipose tissue macrophages of 10 month old, HFD-fed mice that lack Nucb2.
Macrophages sorted directly from Nucb2-/- adipose tissue had significant increases in all but one
studied proinflammatory cytokine levels compared to wild type controls (Figure 3.9). TNF-α
relative expression levels were 1.43 ± 0.04 fold higher (p=0.01), IL-1β 1.6 ± 0.16 fold (p=0.04),
MIP-1α 1.83 ± 0.23 fold (p=0.009) and CCL4 1.44 ± 0.2 (p=0.08) fold higher in Nucb2 -/- mice than
wild type controls.
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Figure 3.9: Nucb2 ablation increases in vivo expression of inflammatory cytokines in obese
adipose tissue macrophages
Relative cytokine expression levels from F4/80+ sorted cells from wild type and Nucb2 -/- mice. (A) TNF-α relative
gene expression levels (B) IL-1β relative gene expression levels (C) MIP-1α relative gene expression levels and (D)
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CCL4 relative gene expression levels. All data are represented as mean ± SEM (n=6 per group). *p< 0.05 relative to
wild type

These data indicated that our in vitro BMDM studies are translated in an in vivo model.
Increases in proinflammatory cytokines in the BMDMs are mimicked in macrophages isolated
from visceral adipose tissue.
RNA sequencing of KO and WT adipose tissue macrophages shows impairments in Type I
interferon signaling
To further investigate the changes induced by the knockout of Nucb2 on the whole
transcriptome of macrophages, we performed RNA-sequencing on F4/80+ isolated macrophages
from visceral adipose tissue. Interestingly, a significant number of genes that were differentially
regulated were interferon stimulated genes (ISG) (41 of the 122 genes). As well as a strong ISG
difference, further analysis showed that several of the upregulated pathways in our model were
those of more M1 like proinflammatory macrophages.
For example, our pathway analyses conveyed that macrophages from Nucb2-/- mice had
a significant increase in tryptophan metabolism as well as glycolysis and gluconeogenesis
pathways. In recent years, a clear association has been made between tryptophan catabolism
and inflammatory reactions in a vast array of disease states [163]. Previous studies show that
nitric oxide production and iNOS transcription rely heavily on tryptophan metabolism [164].
Other groups further went on to show that depletion of tryptophan via the rate limiting enzyme
indoleamine 2,3-dioxygenase (IDO) is the mechanism by which activated macrophages inhibit T
cell activation [165] and is necessary for immune tolerance.
In line with these macrophages being more inflammatory M1 cells is the fact that these
Nucb2-/- macrophages have an increased glycolytic metabolism. It has been shown that
inflammatory M1 macrophages display enhanced glycolytic metabolism and reduced
mitochondrial activity and that conversely, anti-inflammatory M2 macrophages show a high
mitochondrial oxidative phosphorylation state [166]. Furthermore, the stimulation of glycolysis
is an activation signal for macrophages [167]. The fact that these pathways are upregulated in
our macrophages from our Nucb2-/- mice when compared to wild type macrophages might
elucidate a mechanism by which these macrophages are more inflammatory.
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Figure 3.10: Nucb2 ablation alters adipose tissue macrophage transcriptional signatures
RNA sequencing results of adipose tissue macrophages sorted from high fat diet fed Nucb2-/- mice and wild type
mice. (A) Volcano plot with up (red) and down (green) regulated genes and (B) Pie chart expressing percentage of
up (Red) and down (Blue) regulated genes. WT n=6, Nucb2-/- n=5
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Figure 3.11: Nucb2 ablation alters the transcriptome of adipose tissue macrophages
Heat map displaying unsupervised hierarchical clustering of normalized data (A) 58 significantly up regulated genes
and (B) 64 downregulated genes. WT n=6, Nucb2-/- n=5
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Figure 3.12: Nucb2 ablation alters adipose tissue macrophage transcriptome of genes important
for metabolic pathways
Using pathway analysis to uncover a collection of potential molecular interactions and reaction networks (A) major
upregulated pathways in macrophages from Nucb2-/- mice and (B) Percentage of genes involved in type I interferon
responses

These data further elucidate/validate the mechanism by which Nucb2 is regulating immune
cells. It is exciting that some of the major upregulated pathways from our RNA-sequencing is
involved in the metabolism of M1 like proinflammatory macrophages. These data further prove
that ablation of Nucb2 renders macrophages to being more activated to a proinflammatory
state. This proinflammatory state could be resulting in the insulin resistance phenotype seen in
Nucb2-/- mice.
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Insulin resistance and glucose disposal derangements are driven by myeloid specific Nucb2
ablation but not Nucb2 ablation in adipocytes
As shown above, Nucb2 is important in regulating macrophage activation and
inflammatory cytokine production. These data, in combination with the clear insulin resistance
found in the Nucb2-/- mice, led us to investigate the mechanisms underlying this phenotype. We
can think about two opposite cause and effect relationships: 1) Is Nucb2 important in regulating
the immune cells, and the ablation of Nucb2 leads to increased cytokine production, thus
resulting in insulin resistance; or 2) is Nucb2 important for regulating insulin sensitivity in
metabolic tissues directly, independent of the effects on immune cells, which in turn could
potentially activate immune cells? These questions led us to produce tissue-specific, conditional
Nucb2 knockouts.
We therefore crossed our floxed Nucb2 C57Bl/6 mouse with Cre recombinase from the
lysozyme M-encoding locus specific LysMcre driver or adiponectin specific adipoq-Cre to remove
the floxed sequence exclusively in either innate myeloid cells or in adipocytes, respectively. We
then carried out a glucose tolerance test (GTT) and an insulin tolerance test (ITT) in mice fed a
HFD to determine whether Nucb2 ablation, specifically in adipocytes or in myeloid specific cells,
was sufficient to affect glucose homeostasis via insulin resistance.
Initially, we saw no differences in food intake or body weight between the wild type
control, the Nucb2 adipocyte specific knockout and the Nucb2 myeloid specific knockout in both
chow and HFD conditions (Figure 3.13). Strikingly, we observed that the myeloid specific Nucb2 /- mice had significant impairments in insulin sensitivity and impaired glucose tolerance. GTT
revealed that blood glucose levels after glucose injection were significantly higher in LysMcre
Nucb2-/- mice than those in wild type and adipoq-Cre Nucb2-/- animals. We next performed ITT
(0.8 units/kg of body weight) in these mouse models to determine insulin sensitivity. Myeloid
specific Nucb2-/- mice showed a hyperglycemic response to insulin compared to wild-type
littermates as well as adipoq-Cre Nucb2-/- animals.
Together, these data show that ablation of Nucb2 specifically in myeloid cells is sufficient
to replicate the severe insulin resistance phenotype seen in the global Nucb2-/-. This suggests
that Nucb2 in myeloid cells is responsible for the observed physiological impairments which
indirectly lead to significant whole body insulin sensitivity.
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Figure 3.13: Nucb2 ablation in myeloid cells increases insulin resistance and impairs glucose
homeostasis
(A) Body weights of animals fed a HFD were measured weekly from 6 to 12 weeks of age. GTTs and ITTs in Nucb2
specific knockout mouse models and blood samples from the tail were analyzed for glucose concentration. (B) For
GTT, mice that were fed a high-fat diet were overnight-fasted then given an i.p. injection of 10% glucose (4 ul/g of
body weight) and (C) expression by area under the curve. (D) For ITT, mice on high-fat diet were fasted for 4 h before
i.p. administration of insulin, 0.8 units/kg of body weight and (E) expressed by area under the curve. Each point
represents mean ± SEM; n = 5 per group. *P < 0.05.

Overall, these data illustrate that Nucb2 in myeloid cells causes physiological changes
within macrophages, which in turn indirectly affect systemic insulin sensitivity and induce a whole
body insulin resistance state. Taken together with the previous results, Nucb2 is an important
regulator of proinflammatory cytokine production in response to a high fat diet. Without
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regulation of immune cell proinflammatory cytokine production via Nucb2, mice are
constitutively in an inflamed state which can lead to insulin resistance and impaired glucose
uptake.
Macrophage ablation of Nucb2 skews the transcriptome of adipose tissue macrophages
towards a proinflammatory M1-like phenotype
To study how Nucb2 is important in modulating other potential immune pathways, we
tested adipose tissue macrophage transcriptome from LysMcreNucb2-/-. Furthermore, by
comparing the global Nucb2-/- macrophage transcriptome to the macrophage specific Nucb2-/transcriptome would allow us to further delineate potential intrinsic vs extrinsic effects of Nucb2.
Similarly to macrophages isolated from the global Nucb2-/- mice, macrophages from
LysM Nucb2-/- mice also showed interesting changes in their transcriptome. In total, our RNAsequencing from the LysMcre Nucb2-/- mice expressed a difference in 469 genes when compared
to wild type controls, 222 upregulated and 247 downregulated (Figure 3.14). Some of the genes
that were differentially up or down regulated in the myeloid conditional Nucb2-/- mimicked
those of the global Nucb2-/- mice (Figure 3.16). Of major interest to us is serum amyloid A 3
(SAA3). This is a potent proinflammatory protein that has been shown to be elevated in plasma
of diabetic mouse models as well as human studies [168-170].
cre

Under further investigation, our analysis revealed interesting pathways that are either up
or down regulated. Our major upregulated pathways are involved in inflammatory responses
and are transcriptomes of more M1-like macrophages. Not unexpectedly, TNF signaling pathway
was the most upregulated pathway. Other pathways that were up regulated were not as
expected; however they are in line with our increase in proinflammatory cytokine production by
macrophages lacking the Nucb2 gene. For example, HIF-1 signaling pathway was shown to be
increased in our macrophages from LysMcre Nucb2-/- mice. HIF-1 is important in mediating
transcriptional activation of IL-1β [171, 172]. Furthermore, the upregulation of the mTOR
signaling pathway also is known to be required for proinflammatory responses to several disease
states [173, 174].
In concordance to these up regulated pathways being more proinflammatory, some of
our major down regulated pathways are more anti-inflammatory. Although Mitogen-activated
protein kinase (MAPK) can mediate proinflammatory processes, more recent studies suggest that
MAPK has more important roles in mediating anti-inflammatory mechanisms [175, 176]. Our data
suggests a significant downregulation of MAPK in macrophages lacking Nucb2 gene.
Furthermore, our data suggests a decrease in the toxoplasmosis pathway. This is significant
because macrophages infected with toxoplasma strains are polarized towards an M2-like
activation state and secrete anti-inflammatory molecules that can down-regulate Th1 immune
processes. This process is important in the immune response against worm infections. It is
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unclear how or even if Nucb2 is working through this pathway. However, this gives us more
evidence that macrophages lacking Nucb2 are in a chronic proinflammatory state and even show
decreases in anti-inflammatory states.
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Figure 3.14: Nucb2 ablation in macrophages alters adipose tissue macrophage transcriptional
signatures
(A) Heat map displaying the hierarchical clustering of the 1000 most differentially expressed genes (B) Number of
differentially expressed genes with at least a 2 fold increase or decrease. WT n=3, LysMcre Nucb2-/- n=2
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Major Upregulated Pathways

A

Pathway Name

Enrichment Score

Enrichment P-value

TNF signaling pathway
HIF-1 signaling pathway
mTOR signaling pathway

4.99217
3.51362
3.51037

0.007
0.03
0.03

B

Major Downregulated Pathways
Pathway Name

Enrichment Score

Enrichment P-value

MAPK Signaling pathway
Jak-STAT signaling
Toxoplasmosis

9.5822
4.40386
2.98034

0.00006
0.01
0.05

Figure 3.15: Nucb2 ablation in macrophages alters the adipose tissue macrophage transcriptome
of metabolic and inflammatory pathways
Using pathway analysis to uncover a collection of potential molecular interactions and reaction networks (A) major
upregulated pathways and (B) major downregulated pathways

Overall, these data overlap in adipose tissue macrophage transcriptome differences
between global Nucb2-/- and LysMcre Nucb2-/- mice. These similarities suggest that Nucb2 is
playing an intrinsic role in regulating the inflammatory response in macrophages. Furthermore,
the pathway analysis gives us informative insight in to other potential innate immune pathways
that might be modulated or mediated by Nucb2 which contribute to an overall insulin resistance
phenotype. This data clearly show that our macrophages lacking Nucb2 are more
proinflammatory M1-like macrophages.
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Figure 3.16: Nucb2 ablation in macrophages alters the inflammatory transcriptome
From our RNA-sequencing, we determined several overlapping ISG expression levels in macrophages either from
global Nucb2-/- mice or LysMcre Nucb2-/- mice. Differentially expressed genes that overlap between LysMcre Nucb2/- macrophages and macrophages from global Nucb2-/- mice. WT n=3, LysMcre Nucb2-/- n=2

3.4 Discussion
The major findings of these experiments show that 1) Nucb2 is not very important for
immune cell chemotaxis, however, it is an important regulator of M1-like classically activated
proinflammatory macrophages and important for regulating the production of proinflammatory
cytokines as shown by in vitro BMDM model and in vivo sorted macrophages. 2) Nucb2 normally
regulates an inflammatory cascade by down regulating NFκB’s phosphorylation and its
translocation to the nucleus. 3) Nucb2 is critical in mediating type I interferon response, as shown
by significant differentially expressed Interferon-stimulated response genes in macrophages
from wild type vs Nucb2 KO animals. 4) Nucb2 ablation in myeloid lineage cells is sufficient to
cause both decreases in insulin sensitivity and whole body glucose homeostatic impairments.
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These data uncovered the significance of Nucb2 in the regulation of proinflammatory
cytokine production. Not only is Nucb2 important in inflammation, the unbiased transcriptomic
profiling using RNA sequencing suggested that NucB2 deficiency impairs the type I interferon
responses. It is interesting and important to note, however, that these responses are not in an
infectious model, however occurring in a sterile, metabolic challenge with a high fat diet induced
obesity model. We found that Nucb2 is mediating important regulatory functions of NFκB, and
that this regulation maintains basal levels of proinflammatory states.
Nucb2 expression increases in macrophages and T cells under conditions of high fat
feeding. This increase in Nucb2 levels may be a compensatory mechanism to decrease chronicsystemic inflammation in adipose tissue derived immune cells. High fat diet has been shown to
be associated with increased inflammation and inflammatory cytokine production [20, 22, 92,
158] as well as increased nesfatin-1 levels [142, 144]. It is therefore plausible that macrophages
and T cells respond by increasing production of Nucb2 to try to dampen this inflammatory
response. It would also be intriguing to determine if Nucb2 is dysregulated or even becomes
resistant during chronic high fat diet and severe obesity related type 2 diabetes. In fact, one study
implied through correlation studies in cerebrospinal fluid of obese and lean individuals that
nesfatin-1/NUCB-2 has protein binding capabilities, and that differences in protein binding may
be a result of resistance. Finally, the authors show that the efficiency of nesfatin-1/NUCB-2
uptake into CSF is reduced in obese individuals, possibly due to saturation of transporters [177],
however they do mention that further research is necessary. These data are intriguing, however,
these data are potentially spurious due to the unreliable commercially available ELISA kits that
were used in these studies.
Such dysregulation of NFκB in Nucb2 -/- mice could further exacerbate the sterile
inflammatory state in metabolic tissues which in turn renders cells insulin resistant. Interestingly,
other studies have identified that Nucb2 expression correlates positively with plasma levels of IL6 and TNF-α in patients with COPD. The authors of this study concluded that Nucb2 is a novel
inflammatory factor in stable emphysematous COPD, however they did not show a causal
relationship between the two [178]. The authors could have erroneously concluded that such
positive correlation may reflect a proinflammatory connection. Our data strongly suggests that
Nucb2 is positively correlated with proinflammatory cytokine production in an attempt to
decrease inflammatory cytokine production via inhibition of NFκB transcription.
Other studies have shown that Nucb2 mRNA and nesfatin-1 protein levels are significantly
higher in high-fat fed mice (vs chow diet) and are reduced under food deprivation [134]. They
further showed that food deprivation decreases Nucb2 expression in subcutaneous adipose
tissue and that stimulation of subcutaneous adipose tissue explants with TNF-α, IL-6, insulin and
dexamethasone significantly increases intracellular nesfatin-1 levels. Due to non-specificity of
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commercially available reagents, however, these studies with rigorous measures of nesfatin-1
protein levels or effects of nesfatin-1 on cell types cannot be interpreted correctly.
Originally, adipose-tissue-derived peptides (cytokines and adipokines) were thought to
regulate energy metabolism and to be associated with the chronic low-grade inflammation
present in obesity-related metabolic disturbances and inflammatory diseases. In myeloid specific
Nucb2 knockout mice, the inability to regulate macrophage induced-inflammation was sufficient
to cause a diabetic phenotype. Together, our data indicate that Nucb2 is an important regulator
of proinflammatory cytokine production in an NFκB dependent mechanism. Indeed, Nucb2
regulates NFκB activity in cells, though our data do not fully pinpoint at which stage Nucb2
regulates NFκB. We, did, however show that inhibiting the translocation of NFκB reversed all the
inflammatory phenotype seen in macrophages lacking Nucb2. NFκB is usually present in cells in
an inactive state and does not require new protein synthesis in order to become activated. In
fact, in unstimulated cells, NFκB is sequestered in the cytoplasm by a family of inhibitors, IkBs
which become degraded upon cell activation through signaling components. This allows free
NFκB to enter the nucleus and modulates the transcription of many proinflammatory genes. It is
plausible that Nucb2 acts on IkB proteins to maintain NFκB inhibition. However more studies are
required to determine whether upstream pathways that control Nucb2-NFκB interactions.
The RNA sequencing from isolated adipose tissue immune cells has given us many
important insights into the molecular mechanisms by which Nucb2 regulates inflammation and
insulin sensitivity. Interestingly, the majority of the genes that are differentially regulated in
macrophages from Nucb2-/- mice are those of type I interferon response. As well as ISGs, some
of the major pathways that were elucidated were those of inflammatory M1 like macrophage
metabolism. For example, glycolysis and tryptophan metabolism pathways were both up
regulated in the adipose tissue macrophages from our Nucb2-/- mice. Individual genes of great
interest were the increases in Dipeptidyl-peptidase 4 (DPP4) and the increases in acute-phase
SAA3 levels in our Nucb2-/- mice, both of which have been strongly implicated in glucose
metabolism and the development of type 2 diabetes.
To further elucidate the mechanisms by which Nucb2 impact glucose homeostasis, we
generated both adipocyte specific and myeloid specific Nucb2 knockout mice. Our findings
proved that the deleterious effects on insulin resistance is driven mostly by the lack of Nucb2 in
myeloid cells, and not in adipocytes. Following these findings, we investigated functional
differences in adipose tissue isolated macrophages to determine the cause of the metabolic
dysfunction associated with the deletion of Nucb2 (-/-). We therefore performed genome-wide
comparisons of the transcriptomes of adipose tissue macrophages from wild type and Nucb2-/mice. Our RNA-sequencing suggested that Nucb2 is important in regulating type I interferon
response genes, although this has not been rigorously tested.
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DPP4 is a glycoprotein that is ubiquitously expressed (lung, brain, pancreas, kidney, blood
vessels, thymus, lymph nodes and spleen) on the surface of a variety of cells including epithelial,
endothelial and immune cells such as lymphocytes and monocytes [179, 180]. Interestingly, DPP4
can also be cleaved from the membrane and released into the circulation by a process called
shedding [181, 182]. Notably, DPP4 expression is dysregulated in a variety of disease states
including chronic inflammation, cancer, obesity and diabetes. Since DPP4 has been characterized
as an adipokine which correlates with the magnitude of the severity of the metabolic syndrome,
it can be used as a reliable molecular biomarker [183, 184] for this syndrome. Interestingly,
monocytes express high levels of DPP4, and these levels are further upregulated in
proinflammatory states, including those linked to obesity and T2D. Furthermore, a competitive
DPP4 inhibitor, sitagliptin, has been shown to have potent systemic anti-inflammatory
properties, as it suppresses expression of proinflammatory genes in mice and humans and locally
in adipose tissue of obese individuals [185, 186].
Interestingly, our data shows a significant increase of DPP4 expression in adipose tissue
macrophages lacking Nucb2. It is likely that this increase in DPP4 contributes to the overall
inflamed state of the adipose tissue in our Nucb2-/- mice, as well as their insulin resistant
phenotype, via DPP4 mediated activation of NFκB. Furthermore, DPP4 in both its soluble or
membrane bound form, is able to interact with caveolin-1, which leads to a downstream
activation of NFκB via IRAK-1 dependent mechanisms [187, 188]. Finally, DPP4 has been shown
to inactivate the incretin hormone glucagon-like peptide (GLP-1) in the periphery and that DPP4
inhibition increases glucose uptake [189, 190]. Overall, this link with high DPP4 in Nucb2 -/macrophages may affect the bioavailability of its substrates GLP1, which would further decrease
glucose uptake. These data further elucidate a potential mechanism by which Nucb2 is down
regulating adipose tissue macrophage expression of DPP4 which in turn improves glucose uptake.
Another interesting gene target identified from our RNA-sequencing study that may link
Nucb2 to insulin-resistance is SAA. Host response to injury and infection is accompanied by a
rapid rise of blood acute-phase proteins, including SAA [191, 192]. Clinically, increases in SAA
have been widely used as an important indicator in the diagnosis and prognosis of inflammatory
diseases [193-195]. Furthermore, T2D has been shown to be preceded by an acute-phase SAA
secretion, a component of the innate immune system and a sensitive marker for acute
inflammatory state [168, 169]. SAA exhibits significant immunological activity by inducing
secretion and activation of many cytokines (IL-1β, TNF, MIP-1α and IL-6) in macrophages and
lymphocytes, as well as by acting as a chemotactic factor for leukocytes [196-198]. Intriguingly,
SAA3 was the most upregulated gene in our Nucb2-/- isolated adipose tissue derived
macrophages, as compared to wild type macrophages. It is plausible that Nucb2 is functioning
either upstream or downstream of SAA and is necessary to regulate the secretion of many
proinflammatory cytokines.
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Macrophages are cells that are highly regulated by both internal and external signals. To
determine the cell intrinsic vs extrinsic effects of Nucb2 on macrophages, we performed RNAsequencing in the macrophages from myeloid LysMcre Nucb2-/-. Our hypothesis was that
macrophage intrinsic regulation of Nucb2 is responsible for the regulation of inflammatory
cytokine production, which indirectly disrupts insulin sensitivity. Most importantly, ablation of
Nucb2 in myeloid lineage alone is sufficient to render mice insulin resistant. This was evident by
LysMcre Nucb2-/- impairments in insulin tolerance and glucose tolerance test. This shows that
macrophage specific Nucb2 expression is necessary for regulation of obesity related
inflammation and is required for proper maintenance of glucose homeostasis.
Interestingly, we saw many similarities between the global and conditional Nucb2-/macrophage transcriptome, however differences also arose. It is plausible that the similarities
between the global knockout and myeloid conditional knockout exist from the intrinsic effects of
Nucb2. Furthermore, it is plausible that the differences in transcriptomes between these groups
arise from external signals where Nucb2 is affecting different cells, and these cells signal to the
macrophages differently. For example, the up or down regulated genes in the macrophages from
the global Nucb2-/- mice, might be receiving a signal (cytokine) from a T cell which also does not
express Nucb2, whereas the conditional LysMcre Nucb2-/- mice receives a different signal since
those T cells do express the Nucb2 gene. Further studies are required to differentiate the intrinsic
vs. extrinsic effects of Nucb2 on macrophages.
From all our studies, it is clear that Nucb2 is an important regulator of different facets of
the immune-metabolic axis. Of major interest were the findings that Nucb2 is required for proper
regulation of obesity induced inflammation and insulin resistance. Moreover, our RNAsequencing further implicates a novel role of Nucb2 in type I interferon response. From these
results, however, more questions are needed to be answered 1) whether type I interferons
controls metabolism directly? 2) Whether Nucb2 plays a direct role in mediating IFN effects on
metabolism? 3) Whether Nucb2 expression in innate immune cells is required for protection
against viruses?
Although we have studied at Nucb2 during responses to different metabolic conditions,
it remains important to determine the effect of Nucb2 during pathogen-induced immune
responses. To do so, it would be necessary to use our experimental model to determine the role
of Nucb2 in a typical inflammatory response such as lipopolysaccharide induced endotoxemic
challenge. Furthermore, because of the impact Nucb2 has on the interferon response, it is also
imperative to challenge these mice with different viral or bacterial infections (see Ch. 4).
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Figure 3.17: Schematic of how Nucb2 regulates obesity induced inflammation through NFκB pathway
On the left, we are showing what is occurring when we remove Nucb2 from macrophages. The box on the right is the NFκB pathway whereby Nucb2 is acting to
reduce the activity of NFκB which further diminishes the transcription of proinflammatory cytokines.
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Chapter 4: Regulation of Lipopolysaccharide (LPS)-induced Inflammation and
endotoxemia by Nucleobindin-2
4.1 Introduction
Systemic inflammation, resulting from both infections and noninfectious conditions, is a
major cause of morbidity [199, 200]. It can arise from bacterial infection and cause multiple organ
dysfunctions, or can be a result of an external stimulus such as severe burns. Both are different
in nature, however both lead to a dramatic immune response with elevated levels of
inflammation. These responses can result in a cytokine storm with sepsis, which can lead to septic
shock and death. In light of our previous findings that Nucb2 affects the inflammatory sterile
response to obesity, we wanted to see how ablation of Nucb2 may affect the immune response
to well-studied endotoxemia.
Endotoxin is the cell wall component of Gram-negative bacteria, and plays a central role
in the pathogenesis of septic shock. In humans, an injection of small doses of endotoxin (4 ng/kg)
triggers acute systemic inflammatory responses which are qualitatively similar to those that
occur during the onset of septic shock. Indeed, i.v. injection causes direct release of cytokines,
which subsequently cause fever and leukopenia followed by leukocytosis and shock. Shortly after
administration, changes occur in systemic homeostatic processes in many different organs. In
concurrence with organ functional changes, inflammatory mediators are released and contribute
to the responses to eradicate the microbe. These include, but are not limited to, the
proinflammatory cytokines TNF-α, IL-1β, IL-6 and IL-18, as well as chemotactic cytokines MIP-1α
and MIP-1β. There are many major homeostatic pathophysiological derangements during severe
sepsis. Among the changes, hyperglycemia seems to be of most importance. Hyperglycemia
arises from insulin resistance as well as increased muscle glycolysis and lipolysis with subsequent
gluconeogenesis and glycolysis in the liver.
A classic murine model to study systemic inflammation, sepsis and septic shock is the LPSinduced Toll-like receptor 4 dependent systemic inflammation. Although these models are useful
to understand mechanisms, they are somewhat different from the human situation. First,
humans are as much as 100,000-fold more likely to succumb to an intravenous dose of LPS than
mice. An LPS concentration of 1 ug/kg in humans is enough to induce septic shock, whereas mice
require significantly higher concentrations [201]. For studying the onset of systemic inflammation
and the acute innate immune response, murine i.p. injections are good to induce rapid entry of
LPS and acute phase reactions [202]. This is a valuable model to investigate key systemic
responses involving the sympathetic-adrenomedullary axis, acute phase protein production,
inflammation, thermoregulation and alterations in leukocyte responsiveness to endotoxin
agonists prior to the onset of bacteremia (toxicity of these bacteria). It is important to note that
80

endotoxin sepsis, organ failure and ultimately death does not occur as a result of a bacterial
infection, however it ensues by an exaggerated immune response.
Up to now, our findings have underlined the importance of Nucb2 in the maintenance of
the inflammatory processes in both LPS induced BMDMs as well as non-infected responses to
high fat feeding. Therefore, in the present study, we set out to investigate whether NUCB2 is
important in-vivo for the acute inflammatory cytokine response in blood leukocytes in response
to an LPS-induced endotoxemic shock. Injection of LPS into experimental animals is known to
trigger massive production of TNF-α, IL-1β as well as other proinflammatory cytokines which
cause sickness behavior. We examined typical metabolic responses to infection, including core
body temperature, circulating glucose levels, and body weight. We also examined the circulating
levels of typical proinflammatory cytokines in response to LPS-stimulated endotoxic shock.
Finally, we examined the capacity of spleen leukocytes to respond to whole body bacteria after
in vivo exposure to LPS. Our study aimed to test if Nucb2 is required to mount a proper response
to an in vivo endotoxin LPS exposure.

4.2 Materials and Methods
Mice and animal care
Mice were kept in a pathogen-free barrier facility maintained at 22–24°C with a 12:12-h
dark-light cycle (lights on at 0700 h). Mice were housed up to 5 per cage and given ad-libitum
access to normal chow (at least 4.5% kcal crude fat) and sterilized water (hydropac Alternative
Watering System: Seaford, DE, USA). All transgenic and WT mice in our colony were crossfostered to parent cohorts in our colony. The sentinel mice in our animal rooms were negative
for tested standard murine pathogens. Those included ectromelia, epizootic diarrhea of infant
mice [EDIM], lymphocytic choriomeningitis [LCMV], Mycoplasma pulmonis, mouse hepatitis virus
[MHV], murine norovirus [MNV], mouse parvovirus [MPV], murine minute virus [MVM],
pneumonia virus of mice [PVM], reovirus type 3 [REO3], Theiler's murine encephalomyelitis virus
[TMEV], and Sendai virus. These pathogens were tested at various times during the course of the
studies. Chronological changes in body weights were measured during the life of the animals.
Experimental design and LPS injection
Mice were aged to 14-16 weeks before beginning the study. Mice were subjected to
intraperitoneal injection (i.p.) of 2 mg/kg of LPS from Escherichia coli serotype (L3024; Sigma–
Aldrich, St Louis, MO, USA) dissolved in saline solution. In the control group, animals received an
injection with sterile saline solution (NaCl 0.9%). Metabolic measurements were performed at
baseline, 2 hrs and 4 hrs post i.p. injection. Four hours after administration of LPS or saline, the
animals were euthanized with isoflurane and decapitated. All experiments were performed on
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male mice and done at 2hrs and 4 hrs in wild type with saline (n=3 per time point) and LPS (n=3),
as well as in Nucb2 -/- mice with LPS (n=3). All data is combined for an n=6 in each of the three
groups.
Body temperature and blood glucose measurements
Core body temperature was measured using a rectal thermocouple thermometer
Physitemp BAT-12 (Physitemp: Clifton, NJ, USA). Blood glucose was detected using Breeze2 blood
glucose test strips (Bayer HealthCare; Mishawaka, IN, USA) via tail bleed. Measurements were
taken at baseline, 2 hrs and 4 hrs post LPS/saline injections.
Quantitative real time PCR
RNA from tissue and cells were isolated using an RNeasy Plus mini and micro kit (Qiagen;
74106 and 74034) according to the manufacturer's instructions. DNA digestion was performed
on the columns by following the manufacturer's instructions (79254; Qiagen). Following RNA
purification, these samples were then used for iScript cDNA synthesis using a reverse
transcriptase PCR kit (BIO-RAD; Hercules, CA, USA). Quantitative PCR was performed with the
LightCycler 480 II (Roche Applied Science; Indianapolis, IN, USA) and Power SYBR Green detection
reagent (Applied Biosystems by Thermo Fischer Scientific; Woolston Warrington, UK). Primer
sequences for transcripts encoding proteins involved in lipid and glucose metabolism were
designed with Primer Express Software. For Nucb2, we used the forward primer sequence 5'AAAACCTTGGCCTGTCTGAA-3' and the reverse primer sequence 5'-CATCGATAGGAACAGCTTCCA3'. For CCL4, we used the forward primer sequence 5’-GAAACAGCAGGAAGTGGGAG-3’ and the
reverse primer sequence 5’- CATGAAGCTCTGCGTGTCTG-3’. For IL-1β, we used the forward
primer sequence 5’-GGTCAAAGGTTTGGAAGCAG-3’ and the reverse primer sequence 5’TGTGAAATGCCACCTTTTGA-3’. For IL-6, we used the forward primer sequence 5’ACCAGAGGAAATTTTCAATAGGC-3’
and
the
reverse
primer
sequence
5’TGATGCACTTGCAGAAAACA-3’. For TNF-α, we used the forward primer sequence 5’AGGGTCTGGGCCATAGAACT-3’ and the reverse primer sequence 5’-CCACCACGCTCTTCTGTCTAC3’. For MIP-1α, we used the forward primer sequence 5’-ACCATGACACTCTGCAACCA-3’ and the
reverse primer sequence 5’-GTGGAATCTTCCGGCTGTAG-3’.
In all qRT-PCR experiments, 12.5ng cDNA was used. Fold induction of gene expression
with Nucb2 was analyzed with the ΔΔCt method (also known as the comparative Ct method) as
determined by the following equation: ΔΔCt = ΔCt treatment (WT and Nucb2 -/- LPS i.p.) - ΔCt
control (WT control). Here, the ΔCt is the Ct value for the sample treatment normalized to the
endogenous housekeeping gene GAPDH.
Immune profiling by Bio-Plex assay
Concentrations of immune cytokines in sera and BMDM supernatants were determined
using mouse bio-plex pro Th17 cytokine assay (Bio-Plex Pro Array System, Bio-Rad, Hercules, CA,
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USA), following the manufacturer’s instructions. BMDM samples were directly assayed and
serum samples were diluted 1:4 in sample diluent and incubated for 1 h (room temperature, 850
rpm agitation) with capture antibody-coupled magnetic beads. Following three washes in a BioPlex Pro wash station, samples were incubated for 30 min with biotinylated detection antibody
in a dark (room temperature, 850 rpm agitation). Each captured analyte was detected by the
addition of streptavidin-phycoerythrin and quantified using a BioPlex array reader. Analyte
concentrations were calculated with Bio-Plex Manager software.

4.3 Results
LPS-induced endotoxemia significantly alters body temperature and glucose levels
Our previous findings showed strong implications that Nucb2 negatively regulates
metabolic inflammatory responses to obesity. It is thus important to determine if Nucb2 is
important in regulating pathogenic immune response, where inflammation is magnitudes higher
than obesity-induced inflammation. To study the role of Nucb2 on a more pathogen induced
inflammatory response, we used LPS induced Nucb2-/- mice to determine its effects on systemic
inflammation, sepsis and septic shock. To determine this inflammatory responses in the short
term, we challenged WT and Nucb2-/- mice with high doses (2 mg/kg) of LPS from Escherichia
coli via i.p. injections and followed them for 2 and 4 hrs.
At baseline, there were no differences in measured metabolic parameters in the Nucb2/- mice compared to WT animals. At baseline, the body weights of WT mice were 22.83 ± 0.48g,
23.17 ± 0.17g in WT LPS and 22.83 ± 0.48g in Nucb2 -/- (p=0.5). Also, there was no differences in
glucose levels at baseline (WT saline: 134.5 ± 6.0 mg/dl, WT LPS: 144.3 ± 5.48 mg/dl and Nucb2 /-: 145.7 ± 5.94 mg/dl, p=0.2). Finally, there was also no difference in core body temperature
between the three groups (WT saline: 37.95 ± 0.08 °C, WT LPS: 37.98 ± 0.05 °C and Nucb2 -/-:
37.73 ± 0.1 °C, p=0.7).
Interestingly, there was a sharp, significant decrease in blood glucose levels in the short
term response to LPS in both WT and Nucb2-/- mice. The significant decrease in glucose levels
was present 2 hrs after LPS administration (WT saline: 120.0 ± 5.3 mg/dl, WT LPS: 104.3 ± 3.28
mg/dl and Nucb2 -/- LPS: 95.2 ± 5.0 mg/dl, p=0.007). There was no difference in glucose levels
between wild type LPS injected mice and Nucb2 -/- LPS injected mice (p=0.2). The drop in glucose
level was even more dramatic and maintained after 4 hrs (WT saline: 124.7 ± 2.1 mg/dl, WT LPS:
73.2 ± 6.0 mg/dl and Nucb2 -/-: 64.8 ± 2.9 mg/dl, p<0.0001). In total, the wild type LPS had a drop
of glucose levels of 71.2 ± 10.8 mg/dl and the Nucb2 -/- LPS injected mice had a drop of glucose
levels of 80.8 ± 5.0 mg/dl, p<0.0001.
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In parallel to the decrease in glucose levels, there was also significant reductions in core
body temperature in the short term response to LPS. 2 hrs post LPS injection decreased body
temperatures in both WT and Nucb2 -/- animals (WT saline: 37.8 ± 0.03 °C, WT LPS: 36.72 ± 0.24
°C and Nucb2 -/- LPS: 36.85 ± 0.04 °C, p=0.0001). There was no difference in core body
temperature between wild type, LPS injected mice and Nucb2 -/- LPS injected mice, p=0.6. This
drop in body temperature was even more extreme after 4 hrs (WT saline: 37.43 ± 0.13 °C, WT
LPS: 34.95 ± 0.47 °C and Nucb2 -/-: 35.58 ± 0.10 °C, p<0.0001). In summary, LPS injection
decreased body temperature of WT mice by 3.03 ± 0.44 °C and the Nucb2 -/- mice by 2.15 ± 0.17
°C, p=<0.0001.

Figure 4.1: Nucb2 ablation does not affect body weight
Body weights were measured prior to treatment and are represented in grams for wild type sham, wild type LPS
injected and Nucb2-/- LPS injected, 14-16 week old mice. All data are represented as mean ± SEM (n=6 per group).

A
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Figure 4.2: Nucb2 does not alter glucose metabolism during an LPS challenge
Blood glucose levels were measured at baseline, 2 hrs and 4 hrs after injection and are represented as mg/dl. (A)
Glucose levels over time and (B) change in glucose levels from baseline, pre injection glucose levels. All data are
represented as mean ± SEM (n=6 per group). *p< 0.05

84

Body Temp (C )

40

Control
Wild Type LPS
Nucb2 -/- LPS

38

***
36

 Body Temperature

B

Body Temperature

****

34

0

 Body Temp (C)

A

Baseline

2hrs

4hrs

WT LPS

Nucb2 -/- LPS

****

***

-1
-2
-3
-4

32

Control

Figure 4.3: Nucb2 does not alter hypothermic response to an LPS challenge
Body temperatures were measured at baseline, 2 hrs and 4 hrs after injection and are represented degrees Celsius.
(A) Body temperature over time and (B) Change in body temperature compared to baseline, pre injection body
temperatures. All data are represented as mean ± SEM (n=6 per group). *p< 0.05

Ablation of Nucb2 protects against endotoxemic shock and LPS-induced splenic
inflammation
Without an LPS challenge, all studied proinflammatory cytokines are relatively nondetectable in splenocytes from young 14-16 week old, chow fed mice. As expected, LPS injection
initiated a typical acute inflammatory response in mice. Expression levels of different
proinflammatory cytokines significantly increased 4 hrs after the LPS treatment. There was a
fivefold increase in TNF-α (p=0.0006) and IL-1β (p<0.0001) in the spleen of wild type treated mice
versus DPBS sham control mice. LPS administration also increased IL-6 levels over 300 fold
(p<0.0001). Furthermore, expression of macrophage inflammatory chemotactic cytokines was
significantly upregulated in LPS treated mice. MIP-1α expression levels increased 93 fold
(p<0.0001) and CCL4 expression 130 fold (p=0.0005) in LPS treated mice.
Interestingly, LPS also increased the expression levels of these cytokines in the Nucb2 -/mice, however to a lesser extent as the wild type treated mice. In all the cytokines examined,
Nucb2 -/- mice had nearly half the expression of inflammatory cytokines. These data suggest the
Nucb2 deficiency significantly hinders inflammation. Nucb2-/- mice had 70% the level of IL-1 β
(p=0.01) and 48% the levels of TNF-α (p=0.01) when compared to WT treated mice. Furthermore,
Nucb2-/- mice had 60% the level of MIP-1α (p=0.008) and 42% the levels of CCL4 (p=0.02) when
compared to WT treated mice.
Remarkably, LPS alone was able to decrease Nucb2 expression levels in the spleen. Wild
type mice treated with LPS had significantly less Nucb2 expression. Nucb2 levels in the wild type
mice were 43% (p=0.0005) of those of untreated sterile mice.
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Figure 4.4: Nucb2 ablation protects against exaggerated LPS-induced proinflammatory cytokine
expression in spleen
Relative cytokine expression levels in splenocytes from sham- or LPS-treated wild type mice and Nucb2 -/- mice. (A)
IL-1β relative gene expression levels (B) TNF-α relative gene expression levels (C) CCL4 relative gene expression levels
(D) MIP-1α relative gene expression levels (E) IL-6 relative gene expression levels and (F) IL-18 relative gene
expression levels. All data are fold change from control sham injected wild type mice and are represented as mean
± SEM (n=6 per group). *p< 0.05
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Figure 4.5: LPS inhibits Nucb2 gene expression in spleen
Relative Nucb2 expression levels in splenocytes from sham or LPS treated wild type mice and Nucb2 -/- mice. Data
are represented as fold change from control sham injected wild type mice and are represented as mean ± SEM (n=6
per group). *p< 0.05

These data demonstrate that ablation of Nucb2 caused a reduction in proinflammatory
cytokine gene expression when animals were challenged with LPS. Very interestingly, challenging
wild type mice with LPS inhibits Nucb2 expression levels in spleen. Together, the results suggest
that Nucb2 is important in regulating inflammatory cytokine production.
Ablation of Nucb2 protects against endotoxemic shock and LPS-induced systemic circulating
inflammation
We next investigated whether the stimulation of the innate immune system by LPS is
associated with increased levels of circulating inflammatory cytokines. In concordance with the
increases seen in splenocyte cytokine gene expression, LPS challenge significantly increased
serum IL-1β (WT sham vs WT LPS: 322 ± 117 pg/ml and 4323 ± 501 pg/ml, respectively, p<0.0001)
and TNF-α levels (WT sham vs WT LPS injection: 276 ± 149 pg/ml and 1249 ± 144 pg/ml,
respectively p=0.0008). Similarly to splenocyte cytokine gene expressions, Nucb2-/- mice
challenged with LPS also had an attenuation of IL-1β (WT LPS vs Nucb2-/- LPS: 4323 ± 501 pg/ml
and 2646 ± 216 pg/ml, respectively, p=0.02) and TNF-α (WT LPS vs Nucb2-/- LPS: 1249 ± 144
pg/ml and 823 ± 105 pg/ml, respectively, p=0.04) levels in circulation when compared to wild
type LPS challenged mice (Figure 4.6). Loss of Nucb2 had no impact on LPS-induced serum levels
of IFN- γ, IL-10 and IL-17 (Figure 4.6).
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Figure 4.6: Nucb2 ablation protects against exaggerated circulating LPS-induced proinflammatory
cytokine levels
Relative protein levels in circulation in serum from sham and LPS treated wild type and Nucb2 -/- mice. (A) Serum IL1β levels (B) Serum TNF-α levels (C) Serum IFN- γ levels (D) Serum IL-10 levels and (E) Serum IL-17 levels. All data are
represented as pg/ml with mean ± SEM (n=6 per group). *p< 0.05
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These data show that in models of LPS-induced endotoxemia and development of acute
inflammation, loss of Nucb2 lowers innate immune activation as reflected by reduction in
proinflammatory cytokines. Ablation of Nucb2 also decreases circulating levels of
proinflammatory cytokines IL-1β and TNF-α.

4.4 Discussion
From prior data in metabolic inflammation, NucB2 deficiency in macrophages increases
inflammation in response to HFD-induced obesity. These data clearly implicated Nucb2 as an
important regulator of innate immune system in metabolic regulation. Now we are testing
pathogen specific response in a model of LPS induced inflammation where inflammatory
response is several log higher than obesity-induced inflammation.
We show here that ablation of Nucb2 selectively inhibits proinflammatory cytokine
production in vivo during LPS-stimulated endotoxic response. TNF-α has been shown to play a
vital role in the pathophysiology of endotoxic shock. Using mouse models of LPS-induced acute
shock, we tested the effects of Nucb2 ablation on the production of these proinflammatory
cytokines. Our findings indicate that LPS-induced endotoxemia results in similar decreases in
body temperature as well as blood glucose levels in wild type and Nucb2-/- mice. More
intriguingly, absence of Nucb2 inhibited the production of TNF-α and IL-1β, and modified the
production of other cytokines produced by monocytes in both the spleen and in circulation.
We found significant increases in proinflammatory cytokine production in the spleen. The
spleen is a secondary lymphoid organ where there are abundant immune cells responsible for
activation and proliferation of adaptive immunity and clonal expansion for antigen specific
lymphocytes. This increase in cytokines (IL-1β, TNF-α, MIP-1α, CCL4, IL-6 and IL-18) is expected
in response to stimuli. Interestingly enough, Nucb2-/- mice have lower proinflammatory cytokine
production compared to wild type mice. As shown earlier, it is plausible that mice lacking the
Nucb2 gene have basal increases in the level of proinflammatory cytokines and that these animals
are able to mount a faster immune response. This suggests that Nucb2-/- mice are somewhat
protected against LPS induced sepsis.
In circulation, absence of the Nucb2 gene decreased the levels of plasma TNF-α and IL-1β
in response to endotoxemia when compared to LPS challenged WT mice. Although not
significant, Nucb2 -/- mice trended towards having the ability to maintain core body temperature,
a main readout for LPS induced endotoxic shock. It is important to point out that the body
temperature change was only present 4 hours after LPS injection. Also, different doses of LPS
might induce other pathways independent of TNF-α and IL1-β in the development of shock in this
model.
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Interestingly, injection of TNF-α has been shown to attenuate fever and sepsis associated
with LPS endotoxemic response in rats. This was also shown in studies where antiserum against
TNF-α enhanced LPS-induced fever [203, 204]. It is possible that the baseline elevated levels of
proinflammatory cytokines (TNF- α) in Nucb2-/- mice protects these animals (or at least
physiologically limits the response) against exaggerated levels of inflammation during short term
endotoxemia. Moreover, others have shown that dexamethasone (Dexa), a synthetic
glucocorticoid, helps alleviate inflammation, allergic symptoms, and protects against
endotoxemic shock [205]. Consequently, Dexa has been widely used in treatment of sepsis in last
few decades. Dexa also inhibits LPS-induced TNF-α by reducing TNF receptor affinity. Thus, Dexa
counteracts the cytotoxic effect of TNF-α induced sepsis [205]. It is plausible that Nucb2,
downstream or similarly to Dexa, may function as an endotoxin shock resistance protein in an
LPS-induced endotoxemia septic shock model. Very intriguingly, independent studies show that
dexamethasone significantly increases intracellular nesfatin-1 levels [134].
It is necessary to carry out longer term studies to validate and verify whether the Nucb2/- mice are indeed able to resist, or at least contain, increases in inflammation during endotoxic
sepsis. We therefore propose to investigate the physiologic responses to different doses of LPS.
Similarly, we can investigate whether higher doses of LPS cause death in a Nucb2 dose related
effect. This would be necessary as people only succumb to LPS by an exaggerated
immune/inflammatory response and not a bacterial or viral burden. We hypothesize that Nucb2/- mice will be able to resist septic shock, or at least be able to limit the magnitude of response.
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Chapter 5: Discussion and Future Directions
Overall and as presented in Chapter 2, 3 and 4 of this document, our data describe for the
first time the important role of Nucb2 in modulating inflammatory responses and immune cell
activation states in the context of obesity and insulin resistance. Based on our results, previous
data on the identity of nesfatin-1 as a secreted peptide derived from Nucb2 is suspect. We find
that the commercially available antibodies and assays to be non-specific. It is conceivable that
these antibodies react with Calnuc, a highly homologous calcium-binding protein. Contrary to our
initial hypothesis, Nucb2 (or downstream nesfatin-1) is not a satiety factor and in fact does not
impact feeding behaviors. As a consequence, Nucb2 does not affect body weight or adiposity as
evidenced by similar body weight and body composition in WT and Nucb2 -/- mice, regardless of
the composition of the diet. However, our studies show that Nucb2 is an important gene for the
maintenance of obesity induced insulin sensitivity. This effect on insulin sensitivity is however,
secondary to Nucb2’s down-regulation in proinflammatory macrophages and its impact on the
production cytokines in obese adipose tissue.
In chapter 2, we showed that knocking out the Nucb2 gene significantly impairs glucose
disposal rates and therefore insulin sensitivity but only under high fat diet conditions, without
affecting body weight and body fat mass. This was reflected by an almost 50% decrease in the
glucose infusion rate (21.29 ± 2.09 and 11.01 ± 0.94 mg*kg-1*min-1, wild type and Nucb2 -/respectively) necessary to maintain euglycemia in Nucb2-/- mice during a euglycemic
hyperinsulinemic clamp, the gold standard to measure insulin sensitivity in different tissues.
Chapter 3 expands on the data presented in Chapter 2. Due to high expression of Nucb2
in immune cells, we then set out to determine if Nucb2 was involved in different facets of the
immune system. Interestingly, Nucb2 directly down-regulates cytokine production in Bone
Marrow Derived Macrophages (BMDMs) via the NFκB cascade. First, we found that the presence
or absence of Nucb2 in BMDMs primarily impact the proinflammatory classically activated M1
polarized macrophages. This effect is translated in significantly increased production of
proinflammatory cytokines in macrophages lacking Nucb2 as measured by RT-PCR and western
blot analyses. This intrinsic effect was evidenced both using in vitro and in vivo models.
Furthermore, we then determined that the effects on proinflammatory cytokines production
were completely attenuated when the transcriptional activity of NFκB was blocked. Together,
these experiments demonstrate that Nucb2 is required for regulation of macrophage activation,
metabolic inflammation and development of the metabolic syndrome, and that Nucb2 is working
through the NFκB pathway.
Nucb2 is therefore an intrinsic regulator of the inflammatory cytokine production
cascade. To further elucidate the mechanisms by which Nucb2 impact glucose homeostasis, we
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generated both adipocyte specific and myeloid specific Nucb2 knockout mice. Our findings
proved that the deleterious effects on insulin resistance is driven mostly by the lack of Nucb2 in
myeloid cells, and not in adipocytes. This is seen by impairments of insulin tolerance and glucose
tolerance tests in myeloid specific, LysMcre Nucb2-/- mice.
To follow-up these findings, we investigated functional differences in adipose tissue
isolated macrophages to determine the cause of the metabolic dysfunction associated with the
deletion of Nucb2-/-. We therefore performed genome-wide comparisons of the transcriptomes
of adipocyte derived macrophages from wild type and Nucb2-/- mice. Using an RNA-sequencing
approach, we determined that Nucb2 is important in regulating several functional immune
pathways, most being involved in increasing M1-like phenotype and decreasing M2-like
phenotypes. For example, one of the most up-regulated pathways in macrophages from Nucb2/- mice is that of the glycolysis pathway. M1-proinflammatory macrophages use mainly glycolysis
as energy whereas M2-like macrophages utilize mainly oxidative phosphorylation. Others
include increased activity of TNF pathways and tryptophan metabolism. Another very interesting
difference was that involving the type I interferon response genes. It is not known, however, if
type I interferons affect glucose disposal and/or insulin resistance.
Our RNA-sequencing in isolated macrophages from myeloid specific LysMcre Nucb2-/mice elucidated similar transcriptome differences from our isolated macrophages from global
Nucb2-/-. Many of the upregulated pathways are involved in proinflammatory M1-like
macrophage, whereas down regulated pathways are more anti-inflammatory. Due to the
immune systems highly regulated states by both feed forward and feedback loops, future studies
are necessary to determine where Nucb2 is acting on each of these pathways. Are these
pathways up and down regulated as a result of Nucb2 directly or is it down stream to increased
inflammatory state through NFκB pathways.
Overall, the studies presented in Chapter 3 highlight a novel mediator of immunemetabolic cross talk in the context of obesity-induced insulin resistance. Nucb2 is an important
regulator of the inflammatory cascade and is directly regulated by diet/obesity in leukocytes.
High fat diet and/or obesity increase Nucb2 levels in macrophages and T cells. In the absence of
Nucb2, obesity induced proinflammatory macrophages are unable to downregulate
inflammatory cytokines, leading to increased proinflammatory expression. This chronic, lowgrade inflammation, in turn, affects whole body glucose homeostasis and triggers insulin
resistance.
In chapter 4, we further show that Nucb2 is also an important mediator of an
inflammatory immunologic response to endotoxin. We show that Nucb2-/- mice do not have an
exaggerated inflammatory response as seen in wild type mice during endotoxic shock. This is
seen by decreased expression of proinflammatory cytokines in spleen as well as in the systemic
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circulation by decreased IL-1β and TNF-α in Nucb2-/- mice. It is possible that increased levels of
TNF- α and IL-1β in basal Nucb2-/- macrophages serve to first trigger a quick response to LPS and
then contain the overall inflammatory cytokine production.
Future directions
The collected data are very convincing about the role of Nucb2 as a modulator of
inflammation and consequently insulin sensitivity. However, further studies are required for
more mechanistic insights. For example, due to the pleiotropic nature and ubiquitous expression
of Nucb2, it is critical to determine how expression is regulated and how the downstream
peptides, nesfatin-1, nesfatin-2 and nesfatin-3, are also regulated. Also, there is no current
knowledge on whether Nucb2 functions through a receptor and if so what is the receptor(s).
Also, it is important to distinguish between nesfatin-1, -2 and -3 and whether these different
peptides have similar or dissimilar functions. It is possible that these peptides may be regulated
differently by Nucb2 and may therefore act in opposing ways or in synchrony in a physiological
feedback loops way. Further studies will be done by treating Nucb2-/- mice with recombinant
proteins of either nesfatin-1, -2 or -3 alone or in conjunction with one another.
Moreover, our data demonstrates the Nucb2 acts through the NFκB pathway, but does
not indicate through which specific pathway. Does Nucb2 work by decreasing IkB kinase (IKK)
phosphorylation thus leading to a decrease in IkB phosphorylation, and NFκB activation?
Alternatively, does Nucb2 work by a mechanism more upstream of IkB kinase? Furthermore, it is
conceivable that Nucb2 inhibits NFκB through a non-canonical IKK independent NFκB pathway.
For example, Nucb2 may directly inhibit the transcription of the subunits of NFκB, i.e. RelA or
p50. Such a mechanism is possible since the Nucb2 gene encodes for proteins with DNA binding
motifs and since we see a decrease in total NFκB protein expression by western blot. To
unequivocally test where in the NFκB pathway Nucb2 exerts its effects, one can envisage to use
known NFκB inhibitors that work at different steps of the pathway.
Our RNA-sequencing data show that global ablation of Nucb2 affects type I interferon
response genes in macrophages. Type I interferon is secreted by many cell types and stimulates
macrophages and NK cells to elicit an anti-viral response. Interestingly, plasmacytoid (pDC)
dendritic cells are responsible for production of large amounts of IFN-α and IFN-β during antiviral response. Furthermore, according to Immgen database, pDCs have the highest expression
levels of Nucb2. Together, these observations suggest to conduct studies designed to determine
whether the ISG response seen in our macrophage RNA-sequencing is the result of the ablation
of Nucb2 in pDCs? To do this, pDCs from wild type mice and Nucb2-/- mice can be grown in culture
and stimulated with type I interferons. Subsequently, gene expression can be examined to
determine if there are differences between them. Finally, mice can be challenged with IFN-α and
IFN-β to determine if Nucb2 is required for a proper anti-viral response.
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Interestingly, some studies suggest that interferon directly affects glucose tolerance and
insulin sensitivity [206, 207]. It would therefore be interesting to determine if type I interferon
response is involved insulin signaling and thus disrupts glucose metabolism. To determine this,
we propose to stimulate glucose uptake by insulin treatment of cultured hepatocytes in presence
or absence of IFN-α and/or IFN-β. Once the cells are collected, one can measure the levels of
phosphorylation of the different proteins involved in insulin signaling. Such proteins would be
IRS-1, AKT, MAPK and their respective phosphorylated states. Furthermore, as a supplemental
model, one could use a mouse embryonic fibroblast cell line in a similar fashion. If such
investigations indicate a role for type I interferon in insulin sensitivity, it will be necessary to
repeat these studies in an in vivo model. If in vitro and in vivo studies yield similar results, this
would bring even a stronger support (and mechanisms) for our observations of the impact of
Nucb2 on insulin sensitivity.
Finally, immune responses differ drastically depending on the type of infection and
duration. Which other pathways of immune responses are affected by Nucb2? It is first
imperative to repeat the LPS studies with a longer kinetics of the inflammatory response to
determine if Nucb2-/- mice are able to better cope with endotoxemic shock. Our initial studies
suggest that mice lacking Nucb2 are able to maintain lower levels of pro-inflammatory cytokines
compared to wild type mice in response endotoxemia, however this was a short term response
model. It is not clear whether these mice are able to resist LPS induced shock better or if they fail
to mount a proper immune response. Longer term studies will elucidate potential differences
with even death as the endpoint. Furthermore, different infectious diseases and immune stimuli
trigger different immune responses. It would therefore be interesting to challenge wild type and
Nucb2-/- mice with different infectious models (for example lymphocytic choriomeningitis
(LCMV) to determine if different immune responses are being regulated differently by Nucb2. Of
interest, immunosuppressive therapies have been shown to be effective in halting many of the
inflammatory diseases both in humans and in laboratory animals. It is possible that targeting the
activity of Nucb2, or nesfatin-1, -2 or -3, be of interest for pharmacologically halting septic shock.
In summary we propose the following studies:
- Treatment of Bone Marrow derived macrophages with nesfatin-1, -2 and -3 alone or in
combinations to determine which of the downstream Nucb2 peptides is responsible for the
modulation of pro-inflammatory cytokine production. Depending on the results, it will be
important to test whether treatment of live mice (Nucb2-/- and wild type) with nesfatin-1, -2 and
-3 affects glucose uptake and insulin sensitivity.
- Treatment of Bone Marrow Derived Macrophages from wild type mice and Nucb2-/with NFκB inhibitors to test their effects on different proteins in the NFκB pathways. We can
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further elucidate the mechanisms by which Nucb2 is affecting activity of NFκB induced proinflammatory states in macrophages.
- Due to the difference in interferon response genes in our Nucb2-/- macrophages and
the fact that Nucb2 has extremely high expression in plasmacytoid dendritic cells, I propose to
use cultured plasmacytoid dendritic cells from wild type and Nucb2-/- mice to determine if Nucb2
is necessary for interferon response. This would further reveal potential mechanisms underlying
our phenotype.
-Treatment of insulin stimulated hepatocytes with IFN-α and/or IFN-β to determine if
these interferons are directly involved in insulin signaling. Depending on the obtained results,
undertake treatment of wild type and Nucb2-/- mice with IFN-α and/or IFN-β to determine if such
treatment(s) improve the insulin resistance phenotype.
-Challenge the Nucb2-/- mice with longer term LPS infection to determine if mice are
protected from LPS induced septic shock. Furthermore, it will be necessary to use different
infectious models to further elucidate Nucb2’s role in diverse immunologic responses.
-Challenge the Nucb2-/- mice with different infectious models (for example lymphocytic
choriomeningitis (LCMV) and Escherichia coli (E.coli) to determine if different immune responses
are being regulated differently by Nucb2. E.coli would be important to determining if phagocytic
pathways are modulated by Nucb2.
-Determine nesfatin-1, -2 and -3 binding sites which could help identify functional
elements of this protein-DNA interactions. Using either ChIP on chip or ChIP-sequencing to map
global binding sites precisely. This would further elucidate if Nucb2 proteins interact to DNA and
regulate gene expression of different genes.
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Appendix
Glucose Metabolism
In the 19th century, Claude Bernard hypothesized a need for the body to maintain a stable
internal environment, the milieu interieur, which would allow biological processes to proceed
despite variations in the external environment. Bernard’s concept was further developed and
promoted by Walter Cannon, who coined the term “homeostasis” in describing how key
physiological variables are maintained within a predefined range by feedback mechanisms [208].
Indeed, most physiological processes can only operate under a narrow range of conditions and
are maintained by specialized homeostatic mechanisms in the face of variations in the
environment. The body is then able to adjust in response to changes in functional demands and
biological priorities. Deviations in cellular homeostasis engage some type of stress responses,
which is necessary to restore homeostasis. For example, glucose metabolism can be derailed,
leading to dyslipidemia, diabetes, and obesity, while amino acid metabolism seems resistant to
homeostatic dysregulation.
Glycolysis is the pathway by which one glucose molecule is degraded into two pyruvate
molecules in many intermediate steps through enzymatic activity. The chemical reactions begin
when a glucose molecule is phosphorylated to produce glucose-6-phosphate by the enzyme
hexokinase. This reaction consumes one ATP molecule, which is converted to ADP. Glucose-6phosphate is then altered by phosphoglucose isomerase to form fructose-6-phosphate.
Subsequently, fructose-6-phosphate is phosphorylated by phosphofructokinase to form
fructose-1, 6-bisphosphate in a reaction that requires the hydrolysis of one molecule of ATP to
ADP. At this point in the glycolysis pathway, energy in the form of 2 ATP molecules has been
expended. The six-carbon fructose-1,6-bisphosphate molecule is then broken into two threecarbon molecules: glyceraldehyde-3-phosphate and dihydroxyacetone phosphate by an enzyme
dehydrogenase. An enzyme can interconvert these two three-carbon sugars. Next, NAD+ is
reduced to produce NADH as the each glyceraldehyde-3-phosphate molecule is converted via a
kinase to 1,3-bisphosphoglycerate in a reaction requiring inorganic phosphate (Pi). When 1,3bisphosphoglycerate is converted to 3-phosphoglycerate, substrate-level phosphorylation occurs
and ATP is again produced from ADP. Then, 3-phosphoglycerate undergoes two reactions to yield
phosphoenolpyruvate. Next, phosphoenolpyruvate uses pyruvate kinase to convert to pyruvate,
which is the final product of glycolysis. During this reaction, substrate-level phosphorylation
occurs and a phosphate is transferred to ADP to form ATP (Figure).
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Figure: Overview of Glycolysis
The glycolysis pathway is shown in a linear diagram starting at the top with glucose and ending at the bottom with
pyruvate including the intermediates and products throughout.[24]

Lipid Metabolism and Fatty Acid Oxidation
Lipids are physiologically crucial for many biological functions including, but not limited
to, energy storage, signaling and the maintenance of phospholipid membranes. Lipids are either
absorbed from the food we ingest or synthesized by the liver. They are hydrophobic or
amphipathic, mostly insoluble in blood, and require transport within hydrophilic structures called
lipoproteins. These spherical structures possess surface proteins (apoproteins) that are cofactors
and ligands for lipid-processing enzymes.
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The term lipid can be misguiding as it is sometimes used synonymously with fat. Fat,
however, is a subgroup of lipids called triglycerides, while other lipids include cholesterol,
phospholipids and fatty acids. The triglycerides constitute an important part of the lipids that
circulate in the blood, and they are the main constituent of body fat in humans and animals. The
triglycerides are esters derived from glycerol and three fatty acids, and their primary function is
to store energy in adipocytes and muscle cells. Cholesterol, on the other hand, is a ubiquitous
constituent of cell membranes, steroids, signaling molecules and bile acids.
In humans, fatty acids can be formed from carbohydrates, predominantly in the liver and
adipose tissue, from the glycolytic end-product pyruvate. The first step in fatty acid synthesis
starts with the carboxylation of acetyl-CoA, by acetyl-CoA carboxylase, to form malonyl-CoA,
which feeds into the fatty acid synthesis pathway. Acetyl-CoA carboxylase is subject to both
phosphorylation and allosteric regulation and is the point of regulation in saturated straightchain fatty acid synthesis. Dephosphorylation of acetyl-CoA carboxylase is caused by high blood
plasma levels of insulin (e.g. after meals), which in turn promotes the conversion of acetyl-CoA
to malonyl-CoA, and consequently the formation of fatty acids from carbohydrates. On the other
hand, glucagon, which is released into the blood during hypoglycemic conditions and exercise,
causes phosphorylation of acetyl-CoA carboxylase. This in turn inhibits lipogenesis, and favors
fatty acid oxidation via β-oxidation.
In other words, in times of starvation or low energy, the body uses stored fatty acids as
an energy source. β-oxidation is the degradation of fatty acids, and it is named as such because
the oxidation reaction occurs at the second, the β, carbon of the fatty acid chain. Fatty acid
molecules are broken down to acetyl-CoA esters and furthermore are transported into the
mitochondrial matrix to serve as an energy source in this catabolic process. In turn, acetyl-CoA is
generated in the mitochondria and used by the citric acid cycle to produce energy. β-oxidation
also produces co-enzymes FADH2 and NADH, which are transported to the electron transport
chain.
Tricarboxylic Acid Cycle
As previously stated, oxidation of carbohydrates, proteins and fats all converge on the
tricarboxylic acid (TCA) cycle. The TCA cycle is a cycle of reactions starting with acetylCoA, a
product formed from decarboxylation of pyruvate, reacting with oxaloacetate to form citrate.
With the help of enzymes, citrate is then converted to isocitrate, which in turn is converted to
alpha-ketoglutarate and results in the release of CO2. Furthermore, alpha-ketoglutarate is
converted to succinyl-CoA, also releasing CO2. The cycle goes on with the conversion of succinylCoA to succinate, which in turn is converted to fumarate and then to malate. Malate is converted
to oxaloacetate, and the cycle is complete. The oxaloacetate can react with another acetyl-CoA
molecule and the cycle starts over. During the TCA cycle, electrons are transferred to NAD+ and
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FADH, to form the reduced forms NADH and FADH2, which transport the electrons to the electron
transport chain (ETC).

Figure: Overview of Tricarboxylic Acid Cycle
The TCA cycle is shown starting at the top with acetyl-CoA and included the intermediates and products throughout.
The reactions catalyzed by the dehydrogenases that result in NAD+ and FAD reduction and the reactions catalyzed
by succinyl-CoA synthetase, in which GTP synthesis occurs, are highlighted. [24]
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Oxidative phosphorylation
Oxidative phosphorylation, which occurs in the electron transport chain (ETC), is the
synthesis of adenosine triphosphate (ATP) from adenosine diphosphate (ADP) and inorganic
phosphate (Pi). This is an energy-intensive process that consumes O2 and H+-ions to form H2O as
a bi-product. The electrons from the TCA cycle, captured by NAD+ and FADH, provide energy to
complete this process.
The collection of complexes embedded in the inner membrane of the mitochondria
makes up for the ETC. Energy is produced as electrons are transferred from complex to complex
along the ETC. The electrons flow spontaneously through the complexes and are coupled to the
non-spontaneous ejection of H+-ions from the mitochondrial matrix. This creates a membrane
potential and a pH gradient across the mitochondrial inner membrane. The first complex of the
ETC receives electrons from NADH, and the last complex transfers electrons to molecular oxygen,
thus oxygen ions (O2-) are formed. In the mitochondrial matrix, hydrogen ions (H+) immediately
react with the oxygen ions to form the final product, water. The strongly electronegative oxygen
atoms are the final recipient of the electrons. ATP synthase, a reversible proton pump, is coupled
to the ETC, and uses the energy of the proton gradient across the inner mitochondrial membrane
to synthesize ATP.

Intermembrane
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Figure: Overview of Oxidative Phosphorylation
The electron transport chain is shown in this schematic including the protein complexes that lie within the inner
mitochondrial membrane. The different proteins are NADH dehydrogenase in light green; succinate dehydrogenase
in dark green; the acyl-CoA dehydrogenase complex; ubiquinone in green labeled Q; cytochrome c reductase in light
blue; cytochrome c in dark blue labeled cytC; cytochrome c oxidase in pink; and the ATP synthase complex in light
purple. The electron flux is represented by red arrows and e-, and the proton flux is represented by red arrows and
H+.[24]
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